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1.  Introduction 
1.1  Congenital heart disease 
Abnormalities  of  the  heart  before  birth  are  referred  to  as  congenital  heart 
disease  (CHD).  Around  1%  of  live  births  are  affected  (1).  Moreover,  heart 
defects are the leading cause of birth defect-related deaths. Depending upon 
which part of the heart is malformed CHD are classified into different categories 
(2) (Figure 1.1): 
a)  Cyanotic heart disease: This disease includes all malformations that 
cause  deoxygenated  blood  to  bypass  the  lung  entering  the  systemic 
circulation.  This  category  includes  Tetralogy  of  Fallot,  transposition  of 
the  great  arteries,  Ebstein’s  anomaly  of  the  tricuspid  valve,  tricuspid 
atresia, pulmonary atresia, double outlet right ventricle, total anomalous 
pulmonary venous connection and persistent truncus arteriosus. 
b)  Left-sided obstructive lesions: In this category diseases are combined 
that  are  characterized  by  the  failure  of  the  left  ventricle  to  efficiently 
pump  oxygenated  blood  to  all  areas  of  the  body.  Defects  include 
interrupted aortic arch, mitral stenosis, aortic stenosis, aortic coarctation 
and hypoplastic left heart syndrome. 
c)  Septation  defects:  These  defects  result  in  a  mixture  of  aterial  and 
venous  blood  and  results  often  in  volume  overload  of  the  ventricles. 
Defects include  atrial  septation  defects, ventricular septal  defects and 
atrioventricular septal defects. 
d)  Other defects: Bicuspid aortic valve and patent ductus arteriosus. 
Figure 1.1: Congenital heart disease. 
This diagram shows the different parts 
of the adult heart that are affected  by 
congenital  septal  and  valve  disease. 
The  number  in  parentheses  indicates 
the  estimated  incidence  of  each 
disease  per  1,000  live  births.  ASD, 
atrial  septal  defect;  AVSD, 
atrioventricular  septal  defect;  AVD, 
aortic  valve  defect;  VSD,  ventricular 
septal defect; MVD, Mitral valve defect. Image and data adapted from Bruneau et al., 2008 (2). Introduction    2 
Due to its high mortality and morbidity it is important to determine the etiology 
of  the  different  CHD,  which  requires  a  detailed  understanding  of  heart 
development.  This  thesis  focuses  on  the  elucidation  of  molecular  pathways 
governing cardiac valve development as congenital valve defects are with 20 to 
30%  the  most  common  congenital  cardiovascular  malformations  (3).  It  has 
been  estimated  that  about  5%  of  live  births  carry  congenital  heart 
malformations  if  one  also  considers  minor  defects  (1,  4).  Defects  in  valve 
structure  and  function  during  development  occur  in  several  CHD  like  Holt–
Oram, Marfan, Noonan and Williams syndromes for which the genetic cause 
has been identified (5). Mutations in the tbx5 gene cause Holt–Oram syndrome 
(6).  The  Marfan  syndrome  is  due  to  mutations  in  the  fibrilin1  gene,  which 
encodes an extracellular matrix glycoprotein (7). The Noonan Syndrome is an 
autosomal dominant congenital disorder cause in most causes by mutations in 
the  ptpn11  gene  (8)  and  Williams  syndrome  is  caused  by  a  hemizygous 
deletion of about 26 genes in chromosome 7 (9). In addition, mutations of other 
genes  like  notch1  (10)  and  tbx20  (11)  have  been  associated  with  valve 
malformation.  However,  in  many  diseases  the  underlying  cause  of  valve 
malformation remains undiscovered. Thus, it is important to identify genes that 
play a crucial role in cardiac valve and septum formation as well as maturation. 
 
1.2  Cardiac valve development 
All vertebrate hearts, whether four- or two-chambered, have valves to enable 
unidirectional blood flow. Cell lineage analysis in mice as well as in birds have 
demonstrated that the majority of cells in the valves after birth originate from 
the endothelium (12-14) with little or no contribution from other regions of the 
heart  like  myocardium  (12),  proepicardium  (14)  or  secondary  heart  field 
(especially in the outflow tract, OFT) (12).  
  In  mouse  the  primitive  heart  tube  is  formed  by  fusion  of  the  cardiac 
crescent along the embryonic midline at embryonic day  (E) 8.0 (15). At this 
stage the primitive heart tube is composed of a myocardial and an endocardial 
layer, which is separated by a cell-free layer consisting of extracellular matrix 
(ECM)  components  called  cardiac  jelly.  Subsequently,  the  heart  tube  bends 
(looping) and segmentation starts. Shortly after looping cardiac valve formation 
starts with the expansion of the cardiac jelly at the valve forming region i.e. at Introduction    3 
the junction of the future atria and ventricle as well as at the endocardial ridges 
in the OFT. Endocardial cushions (EC) are formed by populating the expanded 
cardiac jelly with mesenchymal cells. These cells originate from the overlaying 
endocardium  by  a  process  called  Epithelial-Mesenchymal  Transformation 
(EMT)  (16,  17).  During  this  process  endocardial  cells  loose  their  epithelial 
characteristics,  delaminate  from  the  endocardial  layer  and  migrate  into  the 
cardiac jelly and form cardiac cushion mesenchyme. In the atrioventricular (AV) 
canal EMT is initiated around E9.5 in mouse (18), HH17 in chicken (19), at 
stages 40-41 in frog (20, 21) and E31 to E35 in human (20). EMT in the OFT 
occurs slightly later (22).  
  Cross talk between endocardium and myocardium through the cardiac 
jelly  is  important  for  EC  formation  (23).  At  the  valve  forming  region  the 
myocardium secrets various signaling molecules, which drive ECM production 
and  inhibit  the  transcription  of  chamber-specific  genes  (Figure  1.2A).  The 
increased amount of ECM and the hydrophilic nature of proteoglycans in the 
ECM  intensify  the  swelling  of  the  cardiac  jelly  and  protrusion  of  the 
endocardium into the lumen (24, 25), which allows unidirectional blood flow at 
this stage. 
 
Figure  1.2:  Scheme  representing  the 
regulatory  mechanisms  that  control  EC 
formation  (A)  and  EMT  (B).  A,  BMP2/4 
induces  transcription  of  Tbx2  in  the 
myocardium  inhibiting  chamber-specific  gene 
expression  and  inducing  deposition  of 
hyaluronan  and  versican  in  cushion-forming 
regions  of  the  AV  canal  and  OFT.  VEGF, 
expressed  in  endothelial  cells,  promotes 
endothelial cell proliferation at EC. B, BMP2/4 expression in the myocardium adjacent to valve 
forming  endocardium  and  multiple  signals  derived  from  endocardium  promote  EMT  in  EC 
(delamination and mesenchymal cells are indicated by white stars). TGFβ promotes EMT by 
signaling  through  Slug,  whereas  Notch1  suppresses  VE-cadherin  (VE-cad)  expression  by 
signaling through Snail promoting EMT. Wnt/β-catenin signaling promotes EMT in EC. After EC 
establishment,  endocardial  VEGF  expression  inhibits  EMT  and  maintains  endothelial  cell 
proliferation at the valve forming region. Image and data adapted from Combs M.D. et al., 2009 
(26). 
 Introduction    4 
The molecular pathways and cellular morphogenesis are conserved in 
AV and OFT cushion development (27). EMT and EC morphogenesis depends 
on  different  signaling  molecules  from  both  myocardium  and  endocardium 
(Figure 1.2B). Participation of cells from the secondary heart field and neural 
crest derived cells add an additional level of complexity to OFT valve formation 
(26, 28). 
 
1.2.1  Key regulatory pathways 
BMP  signaling:  Bone  Morphogenetic  Proteins  (BMPs)  are  multi-functional 
proteins that belong to the Transforming Growth Factor β (TGFβ) superfamily. 
Several in vivo data suggest that myocardium-derived BMPs play a vital role 
during  the  early  stage  of  EC  formation  and  EMT  (29-31).  This  is  further 
supported by in vitro explant culture experiments (32) as well as primary cell 
culture  data  (33).  Before  the  onset  of  EC  formation  BMP2  and  BMP4 
expression  become  restricted  to  the  myocardium  in  the  cushion-forming 
regions of the heart tube. Around E9.5 in mice BMP2 is expressed in the AV 
canal, OFT and atrial myocardium (27, 34) whereas BMP4 is only expressed in 
the AV canal and OFT myocardium (35). In chick BMP2 is also only expressed 
in the AV canal and OFT myocardium (36). In zebrafish BMP4 is expressed 
throughout the primitive heart tube and around 37 hours post fertilization (hpf) 
expression becomes restricted to the AV canal, OFT and inflow tract (IFT) (37).  
BMPs  signal  through  different  serine/threonine  kinase  receptors 
including three type I subtypes [BMPR-IA (ALK-3), BMPR-IB (ALK-6) and type 
IA activin receptor (ActR-IA or ALK-2)] (38) and three type II subtypes [type II 
BMP receptor (BMPR-II), type II activin receptor (ActR-II) and type IIB activin 
receptor  (ActR-IIB)]  (39,  40).  The  transmembrane  receptor  betaglycan  can 
enhance  the  binding  of  BMPs  to  their  receptors  (41).  Activation  of  BMP 
receptors  causes  phosphorylation  of  its  immediate  downstream  targets 
Smad1/5/8. Phosphorylated Smad1/5/8 proteins form a complex with Smad4 
and translocate into the nucleus where they control the transcription of other 
genes  vital  for  EC  formation  (Figure  1.3).  BMP2/4  inhibits  chamber-specific 
gene expression by inducing Tbx2 transcription while promoting expansion of 
the  cardiac  jelly  by  inducing  hyaluronan  and  versican  deposition  in  the  EC 
forming region (26).  Introduction    5 
Figure 1.3: Regulation of BMP 
signaling.  BMP  ligands  are 
secreted  from  the  myocardium 
and  are  localized  in  the  ECM. 
BMPs  signal  through  hetero-
dimerized  ALK3/BMP-RII 
receptors  on  EC  endocardial 
cells.  BMP  binding  activates 
serine/threonine  kinase  activity 
of the receptors which results in 
phosphorylation  of  their 
downstream  target  molecules 
Smad1/5/8.  Phosphorylated 
Smad1/5/8 form a complex with Smad4 and subsequently translocate into the nucleus where 
they control the transcription of different transcription factors regulating EMT. Co-receptors like 
betaglycan  enhance  BMP  binding  to  their  receptors.  Smad6  inhibits  downstream  of  BMP 
signaling  by  antagonizing  the  phosphorylation  of  Smad1/5/8  and  inhibiting  the  complex 
formation of phospho-Smad1/5/8 and Smad4. BMP antagonists like Noggin bind with BMP-2, 
-4 and -7 and block BMP signaling. Soluble Endoglin is thought to inhibit receptor binding of 
BMPs by sequestering them. BMP and TGFβ signaling cross talk via Smad4. 
 
Several experiments have shown that the temporal and spatial control of 
BMP signaling is very important for the proper shape and function of the valves. 
Smad6  for  example  plays  an  important  role  as  negative  regulator  of  BMP 
signaling  (Figure  1.3)  (42,  43).  Consequently,  Madh6  (encodes  the  Smad6 
protein)  mutant  mice  are  characterized  by  excessive  proliferation  of 
mesenchymal cells causing hyperplastic ECs and thickened heart valves (44). 
Other inhibitors of BMP signaling are the secreted, glycosylated protein Noggin 
and the solube Endoglin, which can bind with BMPs antagonizing the binding to 
their receptors (45, 46). BMP signaling inhibition results in downregulation of a 
number  of  genes  including  tgfβ,  notch1,  basic  helix  loop  helix  transcription 
factor twist1 and homeobox gene msx2 which are related to EMT in AV canal 
EC development (34, 47).  
  Taken together, these data demonstrate that BMP signaling is crucial for 
cardiac  valve  formation  by  increasing  production  of  ECM  components, 
induction of endocardial EMT and patterning of the AV myocardium. 
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Wnt/β-catenin signaling: It has been demonstrated that the canonical Wnt/β-
catenin cascade is important for EMT in mice as well as in zebrafish during 
cardiac  valve  development  (48,  49).  In  mice  both  Wnt4  and  Wnt9b  are 
expressed in endocardial cells underlying the EC forming region (26). Recently, 
it  has  also  been  demonstrated  that  in  chick  Wnt9a  is  expressed  at  the  AV 
canal. Overexpression of Wnt9a results in hypercellular cushion and inhibition 
of  Wnt  signaling  leads  to  lack  of  mesenchyme.  In  zebrafish  lack  of  Wnt 
inhibition in apc mutants leads to an increase in the number of AV canal-like 
endocardial  cells  (49).  Taken  together  it  appears  that  the  Wnt/β-catenin 
signaling cascade plays a major role during cardiac valve development. 
 
Signaling via ECM components: The ECM of ECs is a hydrated scaffold that 
not only serves as a physical support for mesenchymal cell migration but also 
provides signaling cues initiating EMT (50). Before the onset as well as during 
the EC formation myocardial and endocardial cells secrete ECM components 
like  ES/130  (a  novel  130-kDa  protein),  hLAMP1  (lectin-associated  matrix 
protein  in  the  heart),  fibronectin,  versican  and  others  that  play  crucial  roles 
during EMT (51, 52). 
  The extracellular polysaccharide hyaluronan (HA) is a major component 
of the ECM in ECs that is synthesized by the enzyme Hyaluronan Synthase 2 
(Has2).  Has2  is  expressed  in  the  myocardium  of  the  AV  canal  region,  the 
endothelium of the OFT and by migratory mesenchymal cells (53). Around E9.5 
cardiac  jelly  is  rich  in  HA  and  versican.  HA  together  with  other  interacting 
proteoglycans  like  aggrecan,  versican,  brevican,  neurocan  etc.  gives  proper 
hydrodynamic properties to the cardiac jelly. HA can also affect cellular events 
by  interacting  with  cell  surface  receptors  like  CD44  and  CD168  (Rhamm) 
transducing intracellular signaling through the Ras and ERK pathways (54, 55). 
In  mice  disruption  of  the  has2  gene  prevents  transformation  of  cardiac 
endothelial  cells  into  mesenchyme  (53).  Interestingly,  heterodimerized 
ErbB2/ErbB3 receptor in Has2 mutant failed to phosphorylate. Using AV canal 
explant cultures Camenisch et al. could rescue this phenotype by adding the 
ErbB3 ligand, neuregulin (also known as heregulin-1). These data suggest that 
there  is  a  link  between  hyaluronan  and  ErbB  receptor-mediated  signaling 
during EMT in ECs (28).  Introduction    7 
  Versican, an extracellular matrix proteoglycan, plays an important role 
on  cellular  proliferation,  migration  and  differentiation  via  interacting  with  cell 
surface receptors. In mice versican is expressed in the EC of the cardiac valve 
forming  region  (56).  In  zebrafish  versican  is  expressed  during  early 
development throughout the cardiac myocardium and its expression becomes 
restricted at 37 hpf to the AV canal region (37). Versican can bind with CD44 
and stabilizes its interaction with HA. It also has been suggested that versican 
can  interact  with  β1  integrin  and  activate  focal  adhesion  kinase,  which 
promotes cell adhesion (57). However, a number of studies have shown that 
versican has anti-adhesive properties (58, 59). Mutation of the mouse cspg2 
gene encoding versican caused failure of endocardial cells to undergo EMT 
and to migrate into the cardiac jelly of cardiac valve primordia (56, 60).  
  Taken  together,  these  data  demonstrate  that  the  components  of  the 
ECM play important roles during valve development beyond their function as 
physical support. 
 
1.3  Zebrafish heart development 
In  this  thesis  we  used  the  zebrafish  as  model  system.  Cardiogenesis  in 
zebrafish starts at the early blastula stage (2.75 hpf, 512 cells) (see appendice, 
Table A1), when most cardiac progenitors are located at the marginal zone, 
midway between the dorso-ventral axis. At the pregastrula stage (5 hpf, 40% 
epiboly) atrial myocardial progenitors are ventrally and ventricular myocardial 
progenitors  are  more  dorsally  positioned.  Endocardial  progenitors  are  not 
spatially organized (61, 62). During gastrulation (5.5 hpf to 8 hpf) pre-cardiac 
cells involute and migrate towards the animal pole. At around the 6 to 8 somite 
stage (11.5 hpf) the migratory cardiac progenitor cells reach the embryonic axis 
and form part of the anterior lateral plate mesoderm (ALPM), that expresses 
the pre-cardiac marker nkx2.5 (63). Around this stage gata4 is expressed within 
rostral  (anterior)  and  caudal  (posterior)  ALPM  and  hand2  expression  is 
restricted to the caudal portion of gata4-expressing ALPM. nkx2.5 expression is 
observed within a medial portion of the caudal ALPM, but is excluded from the 
lateral and rostral ALPM (Figure 1.4) (64).  
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Figure 1.4: Scheme of the ALPM superimposed onto a dorsal view 
of a live embryo at the 7 somite stage. The tip of the notochord is 
outlined  by  dashes.  The  ALPM  is  divided  in  zones  correlating  with 
expression patterns described in the text: rostral (white), medial (black), 
and  lateral  (gray)  ALPM.  However  during  the  6  to  9  somite  stage 
(11.5 hpf)  ALPM  morphology  slightly  varies.  Modified  image  adapted 
from Schoenebeck et al., 2007(64). 
 
  In between the somite stages 10 to 16 (14-16 hpf), the nkx2.5-positive 
cells  migrate  medially.  The  initiation  of  myocardial  differentiation  starts  at 
somite stages 13 to 14 (15 hpf) and the cardiomyocyte-specific genes cmlc2 
and vmhc are expressed (65). Atrial-specific gene expression is first evident at 
the 19 somite stage. At the 16 somite stage cardiomyocyte progenitors form a 
pair  of  bilateral  tubular  primordia  that  are  positioned  on  either  side  of  the 
endocardial progenitor cells. The ventricular precursor cells (vmhc-positive) are 
medially and atrial precursors are laterally positioned. These lateral populations 
migrate towards the embryonic midline in an  organized fashion (65). Proper 
myocardial  differentiation  and  differentiation  of  the  closely  juxtaposed 
endodermal  precursors  are  a  prerequisite  for  the  migration  of  both  lateral 
myocardial populations (66-68). There are two possibilities: either endodermal 
precursors  provide  factors,  which  induce  cardiomyocyte  migration  or  they 
produce a substrate for migration. At around the 18 somite stage myocardial 
precursors reach the midline and begin to fuse at the posterior point to form a 
horseshoe-shaped  structure  (66).  Around  the  somite  stage  21  anterior  cells 
migrate  medially  and  the  horseshoe  transforms  into  a  cone  with  a  central 
lumen. At 22 hpf the cone shape gets transformed into a tube (66, 69). First the 
ventricular end of the heart tube organizes and then the atrial end. By 24 hpf, 
the tube lies along the anterioposterior axis with the atrial end anteriorly and 
ventral end posteriorly (Figure 1.5) (65).  
After cardiac tube formation neural crest cells migrate to the linear heart 
tube and  differentiate into cardiomyocytes. Incorporated  cardiac neural crest 
cells  express  myocardial  markers  during  the  initiation  of  cardiac  looping 
morphogenesis (30 hpf) (70, 71). Cardiac contraction begins at around the 27 
somite  stage  (22  hpf).  In  zebrafish,  after  cardiac  contraction  begins,  intra-
cardiac hemodynamics and myocardial patterning play a crucial role for cardiac 
valve morphogenesis and trabeculation  (72, 73).  After primitive heart tube Introduction    9 
Figure  1.5:  Anatomical 
position of the myocardial 
progenitors  during  heart 
tube  assembly.  (A-H) 
Dorsal views anterior at the 
top  showing  the  cmlc2-
positive and on the bottom 
the  vmhc-positive 
myocardial population. At the 16 somite stage, cmlc2-positive cardiac precursors remain as two 
bilateral tubular primordia. Ventricular progenitors are positioned anteriorly. At the 18 somite 
stage, cardiac fusion begins via contact between two populations established at the posterior 
point  (arrowheads  in  B,F)  to  form  a  horseshoe-shaped  structure.  At  the  21  somite  stage, 
anterior cells migrate medially and the horseshoe transforms into a cone with a central lumen. 
By 24 hpf, the cone is extended into a primitive heart tube. At this time point ventricular cells 
are almost completely assembled while the atrial precursors (arrow in D) are still scattered. 
Modified images are adapted from Yelon et al., 1999.(65). 
 
formation cardiac ballooning and looping starts and visibly distinct ventricular 
and atrial chambers are formed at around 30 hpf. At 3 days post fertilization 
(dpf) there are four visibly distinct chambers formed i.e. juxtaposed atrium and 
ventricle,  sinus  venosus,  and  bulbus  arteriosus,  which  are  separated  by 
constrictions (Figure 1.6). Cardiac valve formation at the AV junction starts at 
36  hpf  with  the  initiation  of  cardiac  jelly  deposition  and  endocardial  cell 
differentiation.  Like  mammalian  and  avian  hearts  the  adult  zebrafish  heart 
contains  a  coronary  vasculature  and  a  third  cellular  layer  surrounding  the 
myocardium, the so-called epicardium (74). The myocardium remains devoid of 
an epicardium until 48 hpf. Like other vertebrates the epicardium in zebrafish 
develops from the proepicardial organ (PEO) (75). At 50 hpf there are two PEO 
visible  in  zebrafish  hearts  as  clusters  of  cells.  A  similar  structure  has  been 
described in mouse and avian PEO. One of the clusters is situated near the 
sinus  venosus  and  the  second  one  on  the  ventricular  surface  of  the  heart 
adjacent to the AV junction. On the third day of zebrafish development PEO 
cells  start  to  migrate  on  the  top  of  the  myocardial  layer  and  by  4  dpf  the 
embryonic epicardium surrounds the myocardium (75). Signaling cues as well 
as cellular contribution from the epicardium are essential for proper coronary 
vasculature  morphogenesis,  ventricular  trabeculation  and  overall  myocardial 
growth and differentiation (76).  Introduction    10 
Figure  1.6:  Cardiac 
morphogenesis  after  primitive 
heart  tube  formation.  (A,B) 
Brightfield images of the wild type 
embryos heart after whole-mount in 
situ  hybridization  with  probe 
against  cmlc2.  (A)  Around  30  hpf 
the  primitive  heart  tube  has 
become curved and visibly distinct 
ventricular and atrial chambers are 
formed.  (B)  A  looped  heart  at 
52 hpf, the ventricle is to the right 
and atrium to the left of the midline 
and  constriction  is  evident  at  the 
AV  boundary.  (C)  H  &  E  stained 
saggital section of a heart from a wild type embryo at 72 hpf is showing four visibly distinct 
chambers formed in a series i.e. sinus venosus, atrium, ventricle, and bulbus arteriosus; blue 
arrow indicates the bulbus arteriosus. (D) Confocal image of the heart from Tg(myl7:EGFP-
HsHRAS)
s883  embryos
  (EGFP  localized  in the
  cardiomyocyte  membrane)  at  72  hpf  showing 
small clusters of cardiomyocytes (trabeculae) on the single layer of ventricular myocardium; 
indicated by arrow. Red arrows indicate the AV boundary. A; Atrium, V; Ventricle, SV; Sinus 
venosus, OFT; Outflow tract, IFT; Inflow tract. Modified images are adapted from Auman et al., 
2007 and Qu et al., 2008 (77, 78). 
 
  In  the  zebrafish  heart  ventricular  trabeculation  is  initiated  at  around 
72 hpf.  At  this  time  point  ventricular  cardiomyocytes  make  small  clusters  of 
cells  on  the  monolayered  myocardium  and  protrude  inside  the  ventricular 
lumen (Figure 1.6D). Afterwards they grow further and make complex finger 
like projections on the compact myocardial layer. A recent study has suggested 
that  the  initiation  of  ventricular  trabeculation  starts  with  cardiomyocyte 
delamination and migration. Later on trabecular growth depends on cell division 
(79).  Every  part  of  the  adult  zebrafish  heart  is  evident  at  5  dpf  heart,  i.e. 
epicardium, endocardium, myocardium, trabeculation of the ventricular wall as 
well as cardiac valves at the AV junction and OFT. 
 
1.3.1 Atrioventricular canal morphogenesis 
At 30 hpf the heart consists of a single layer of myocardium and a single layer 
of  endocardium  that  are  separated  by  cardiac  jelly.  At  this  time  ventricular 
myocardial  cells  are  cuboidal  (80).  In  contrast,  atrial  myocardial  cells  are Introduction    11 
squamous.  Cardiomyocytes  at  the  AV  boundary  have  no  obvious  specific 
morphology. Endocardial cells are squamous throughout the endocardium (81).  
  Differentiation of the myocardial as well as endocardial cells at the AV 
boundary  starts  around  36  hpf.  A  single  tier  of  endocardial  cells  starts  to 
differentiate transforming into cuboidal shaped cells, whereas the rest of the 
endocardial cells remain squamous. Differentiating endocardial and myocardial 
cells express ECM components resulting in the swelling of the cardiac jelly at 
the AV boundary. The number of differentiated cuboidal endocardial cells at the 
AV  boundary  increases  gradually.  At  2  dpf  a  five  to  six  cell-wide  sheet  of 
differentiated  endocardial  cells  (cuboidal)  lines  the  superior  and  inferior  AV 
boundary regions. These differentiated cuboidal endocardial cells express Dm-
grasp  (Alcam),  whereas  squamous  chamber  endocardial  cells  are  devoid  of 
Dm-grasp. At this developmental stage this  cellular structure  prevents blood 
regurgitation (81).  
  The  swelling  of  the  cardiac  jelly  and  the  right  combination  of  ECM 
components is crucial for AV canal differentiation and valve formation (16). The 
expression  of  genes  important  for  AV  canal  differentiation  and  cardiac  jelly 
swelling, like has2, bmp4, cspg2, tbx2 and notch1b, becomes restricted to the 
AV  boundary  region  during  AV  canal  morphogenesis  (37,  82).  The 
differentiation of the AV endocardial cells is continued until 55 hpf. At 60 hpf 
differentiated AV endocardial cells start to form valve leaflets, which transform 
into functional leaflets at around 96 hpf (81, 83). During this invagination (60 to 
96 hpf) cuboidal AV endocardial cells are round in appearance and lose their 
Dm-grasp expression (Figure 1.7) (81, 83).  
  There is a debate about the mechanism of valve leaflet development. 
Beis  et  al.  have  suggested  that  the  zebrafish  valve  leaflet  forms  from  a 
preexisting endocardial cushion similar to mammalian and avian (81). Recently, 
with the help of high-speed imaging of the zebrafish heart valve development 
Scherz et al. suggested that valve leaflets form directly by invagination of the 
endocardium  but  not  by  EMT  (83).  However,  the  structure  of  mature 
mammalian, avian, and amphibian AV valves is similar to adult zebrafish valves 
consisting  of  complex  stratified  connective  tissue  (74,  84)  (Figure  1.7). 
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in valve formation are conserved among species. This assumption has been 
substantiated by several experimental approaches (26, 74). 
 
Figure 1.7: AV valve morphogenesis between 36 hpf and 7 dpf. (A,B,C) Confocal images of 
the heart is showing Tg(flk1:EGFP)
s843 (pseudo-colored blue) embryos immunostained for Dm-
grasp (pseudo-colored green) and stained with rhodamine phalloidin (red). (A) At 36 hpf the 
heart has partially looped and the endocardial cells are squamous, except one cell at the AV 
boundary, which is cuboidal expressing Dm-grasp (arrow). (B) At 55 hpf 5 cells in the superior 
AV canal and 4 cells in the inferior AV canal region exhibit a cuboidal shape and express Dm-
grasp. In contrast, chamber endocardial cells are Dm-grasp-negative. Myocardial cells adjacent 
to the AV canal exhibit stronger Dm-grasp expression compared to the chamber myocardium. 
(C)  At  60  hpf  differentiated  endocardial  cells  start  to  develop  valve  leaflets  (inset  shows 
schematic  drawing  of  superior  AV  endocardial  cells).  (D)  Confocal  image  of  the  heart  is 
showing that at 7 dpf valve leaflets consist of two layers of Tg(Tie2:EGFP)
s849 (pseudo-colored 
blue)-positive  cells  (arrowheads),  which  are  devoid  of  Dm-grasp.  (E)  There  are  four  valve 
leaflets  in  the  adult  zebrafish  AV  canal  (arrowheads).  A;  Atrium,  V;  Ventricle,  AVC; 
atreoventricular canal, sup; superior AVC, inf; inferior AVC. Modified images are adapted from 
Beis et al., 2005 (81). 
 
1.4  Nephronectin 
We have recently discovered that Nephronectin is transiently expressed in the 
heart at the time of valve formation. Nephronectin (Npnt) is an ECM protein 
encoded  by  the  gene  npnt.  Npnt  contains:  an  N-terminal  signal  peptide  for 
protein  secretion,  Ca
2+-binding  EGF  domains  that  can  bind  to  growth  factor 
receptors, a Mucin-like domain indicating that Npnt can be glycolysated, a RGD 
sequence that can bind to integrins and a C-terminal MAM domain suggesting 
an  adhesive  function  (Figure  1.8).  These  domains  are  conserved  among 
species, however, the number of EGF repeats are variable. Zebrafish Npnt has 
65-70% homology compared to mammalian Npnt (see appendices, Figure A1). 
The predicted size of mouse Npnt is 63 kDa whereas the secreted Npnt runs 
on a denaturating gel like a protein of ≈120 kDa. This difference is probably due 
to glycosylation of the core protein (85, 86). Nephronectin has been described Introduction    13 
as  a  ligand  of  integrin  α8β1  having  a  higher  affinity  than  the  RGD  motif-
containing  proteins  fibronectin,  vitronectin,  osteopontin  and  tenascin-C  (85). 
However, it can also bind with several other RGD-binding integrins (87). 
 
 
 
 
Figure 1.8: Scheme representing different protein domains of Nephronectin. 
There are two variants of Npnt known in mammals. Both have the same 
domain  structure,  however,  one  variant  has  one  more  exon  encoding  ≈18 
amino  acids.  There  is  no  data  available  demonstrating  that  these  variants 
behave differently. In zebrafish only one variant is known. Npnt is expressed in 
many developing organs like jaw, ear, eye, urogenital system, digestive tract, 
lung, branching epithelia etc. with a prominent expression in tissues undergoing 
EMT (87). Mouse lacking Npnt has shown delayed invasion of the metanephric 
mesenchyme  by  ureteric  bud  during  early  kidney  development  resulting  in 
kidney agenesis or hypoplasia. This developmental problem in Npnt knockout 
mice  is  associated  with  the  reduced  expression  of  the  TGFβ  superfamily 
protein GDNF; a vital regulator of ureteric bud morphogenesis (88). It has also 
been shown that GDNF expression is reduced in integrin α8 null mice (89). 
These  data  indicate  that  Npnt  plays  a  vital  role  during  ureteric  bud 
mesenchyme  migration  by  regulating  GDNF  expression  via  integrin  α8β1 
receptor.  Another  study  suggests  that  Npnt  is  associated  with  tubular 
epithelium  regeneration  in  nephrotoxic  acute  tubular  necrosis  (90). 
Furthermore,  it  has  been  associated  with  malignant  melanoma.  Stable  Npnt 
overexpression in melanoma cell lines increased cell adhesion and decreased 
cell  migration  (91).  In  vitro  data  on  the  MC3T3-E1  osteoblast  cell  line  has 
shown that TGFβ strongly inhibits Npnt expression by activating ERK1/2 and 
JNK pathway (92). Another study supports this  by  demonstrating that TGFβ 
inhibits Npnt-induced osteoblast differentiation (93). Subsequently, it has been 
suggested, that early osteoblast differentiation is dependent on EGF repeats of 
Npnt mediating ERK signaling (Figure 1.9) (94). Taken together Npnt is playing Introduction    14 
an  important  role  in  cell  migration  and  differentiation  activating  integrin  and 
MAP kinase signaling pathways.  
 
Figure  1.9:  Model  of  intracellular 
signaling  via  Npnt-EGF  repeats  and 
inhibition  of  Npnt  expression  by  TGFβ. 
Binding  of  TGFβ  ligand  to  its  receptor 
activates  ERK1/2  and  JNK  signaling 
cascade  which  inhibits  Npnt  expression. 
Extracellular Npnt can bind with its receptor 
via  EGF  repeats,  results  ERK1/2 
phosphorylation  and  activation.  Activated 
ERK1/2  regulates  transcription  of  different 
genes vital for cellular differentiation.  
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1.5  Aim of the study 
In order to better understand heart development Dr. Engel has performed a 
large scale expression study describing the expression of over 28000 genes 
during  rat  heart  development  from  E11  to  postnatal  day  P10.5.  Genes  that 
significantly  changed  in  expression  were  clustered  based  on  their  temporal 
expression profile and could be associated to morphological changes. The goal 
of this approach is to identify novel regulators of heart development. 
  The aim of this thesis was to verify the hypothesis derived from the large 
scale  expression  study  that  Nephronectin  is  a  novel  regulator  of  heart 
development.  As  a  model  system  the  zebrafish  was  chosen  due  to  the 
advantage  that  a  zebrafish  embryo  develops  externally,  is  translucent  and 
continues to grow for several days despite developing a severely malformed, 
non functional heart. The specific aims of this study were: 
 
Aim 1:  Determining  the  spatiotemporal  expression  pattern  of  Npnt  during 
mammalian and zebrafish heart development. 
Aim 2:  Assessing the function of Npnt during zebrafish heart development by 
utilizing morpholino-based antisense technology to knock down Npnt. 
Aim 3:  Elucidating the downstream signaling cascade of Npnt during heart 
development. 
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2.  Materials  
2.1  Equipment 
2.1.1  Miscellaneous equipment 
The equipment listed in Table 2.1 was used in this work.  
Table 2.1: Name, model and supplier of used equipment. 
Equipment  Model  Supplier 
Aliqouting pipette  Repeater Plus  Eppendorf 
Agarose gel 
electrophoresis chamber 
B2 Separationssystem  OWI 
Aquatic system    Tecniplast 
Bacterial incubator  InnOva 4200  New Brunswick 
Scientific 
Balance  ALC 3100.2  Acculab 
Sartorius  Belly dancer  The belly dancer  Stovall 
Chemical hood  Vinitex Air  Vinitex 
CO2 incubator  Galaxy R  New Brunswick 
Scientific 
CO2 incubator  Innova co-170  New Brunswick 
Scientific 
Heating block  Digital Heatblock  VWR 
Homogenizer  Ultra turrax T8  IKA Werke 
Hybridization oven  HB 1000 Hybridizer  UVP Laboratory 
Products 
Injection pump  Pneumatic PicoPump PV820  World Precision 
Instruments 
Laminar flow  Hearasafe KS  Heraeus 
Luminescent Image 
analyzer 
LAS-4000   FujiFilm 
Magnetic heating plate  Combimag RCT  IKA Werke 
Magnetic stirrer  Stirrer  VWR 
Micromanipulator  MM33-right  World Precision 
Instruments 
PCR cycler  Gene Amp PCR System 9700  Applied 
Biosystems 
pH Meter  pH 221 Microprocessor pH 
Meter 
HANNA 
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Equipment  Model  Supplier 
Pipettes 2,5µL; 10µL; 
100µL; 200µL 1000µL 
Research  Eppendorf 
Plate reader  NanoQuant  Tecan 
Power supply  EV243; EV231  Consort 
Real-time PCR cycler  CFX96 Real-Time System 
C1000 Thermal Cycler 
BioRad 
Roller mixer  SRT6  Stuart 
Rotator  SB3  Stuart 
SDS-PAGE 
electrophoresis chamber 
X Cell Sure Lock  Invitrogen 
Shaker  MHL20  HLC 
Spectrophotometer  NanoDrop 2000c  PeqLab 
Thermo-block  Digital heat block  VWR 
Transfer chamber  X Cell II Blot Module  Invitrogen 
Transilluminator  Gel ix DNA and Protein imager  Itas 
Vacuumpump  Diaphragma Vacuum pump  Vacuubrand 
Vortex  VV3  VWR 
Waterbath  U3  Sulabo 
 
2.1.2  Microscopes  
The microscopes used in this study are listed in Table 2.2. 
Table 2.2: Microscope type, model and supplier of used centrifuges. 
Microscopes  Model  Supplier 
Binocular  Leica S6  Leica 
Confocal microscope  Axio Imager Z.1  Zeiss 
Fluorescence 
microscope 
Leica DMI 3000 B  Leica 
Fluorescence 
microscope 
Leica DM 6000 B  Leica 
Microscope  Axiovert 25  Zeiss 
Stereo microscope  Leica MZ 16FC  Leica 
 
2.1.3  Centrifuges 
The centrifuges used in this study are listed in Table 2.3. 
Table 2.3: Centrifuge type, model and supplier of used centrifuges. 
Centrifuge   Model  Supplier 
Cooling centrifuge  Universal 320R   Hettich Zentrifugen 
Cooling table centrifuge  Heraeus Fresco 17  Heraeus 
Tabel top centrifuge  Centrifuge 5415C  Eppendorf Materials    18 
2.2  Miscellaneous materials 
2.2.1  Disposables 
The disposable materials listed in Table 2.4 were used in this work. 
Table 2.4: Product, type and supplier of used disposable materials. 
Materials  Type  Supplier 
Aliquoting pipette tips  Combitips   Greiner bio-one 
Bacterial culture tubes   14 ml PP Tube  Greiner bio-one 
Capillary tubes  0.2 mm  World Precision Lab 
Cell culture dishes   10 cm  Greiner bio-one 
Cell culture plates  24 and 6 Well Plates  Greiner bio-one 
Cell scraper  Cell Scraper  Greiner bio-one 
Coverslips  24x50 mm  Menzel Gläser 
Coverslips  12 mm diameter  Menzel Gläser 
Filter paper  Chromatography (3 mm)  Whatman 
Injekt   1ml  Braun 
Latex gloves  Satin plus  Kimtech 
Microscope slides  Mattrand, geschliffen 
76x26 mm 
Knittel Glaser 
Microscope slides  Super frost ultra plus  Menzel Gläser 
Nitril gloves  Activ Aloe  Blossom 
Nitrocellulose transfer 
membrane 
Protran Nitrocellulose  Whatman 
PCR tubes  0.5 ml  Eppendorf 
Pipette filter tips  FT10; FT100; FT200; 
FT1000 
Greiner bio-one 
Pipette tips   10 µl; 200 µl; 1000 µl  Greiner bio-one 
Plastic pipettes  2 ml; 5 ml; 10 ml; 50 ml 
cell star 
Greiner bio-one 
PAGE  NuPAGE 4-12% Bis-Tris 
Gel 1.0 mm X 12 well 
Invitrogen 
PAGE  NuPAGE 4-12% Bis-Tris 
Gel 1.5 mm X 10 well 
Invitrogen 
Reaction tubes 1,5ml; 
2ml 
Safe Lock Tubes  Eppendorf 
Reaction tubes 15ml; 
50mL 
Cell Star TUBES  Greiner bio-one 
Thin pipette tips for 
kapillary filling 
20 µL Physio Care 
Concept  
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Materials  Type  Supplier 
Tissue culture flasks  T75  Greiner bio-one 
Tissue culture flasks  T25  Greiner bio-one 
Transfer pipettes  Transfer Pipettes  Sarstedt 
 
2.2.2  Non-disposables  
The reusable materials listed in Table 2.5 were used in this work. 
Table 2.5: Product, type and supplier of used non-disposable materials. 
Materials  Type/Purpose  Supplier 
Glass beaker  DURAN  Schott 
Forceps  Inox.4  Dumont 
Glass bottles  DURAN  Schott 
Glass erlenmeyer flasks  DURAN  Schott 
Glass measuring 
cylinder 
DURAN  Hirschmann 
Glass pipettes  2 mL; 5 mL; 10 mL; 25 
mL 
Brand 
Micro scale  019.96843 1 mm in 100  Novex 
Hemocytometer  0.1 mm depth; 0.0025 
mm
2 
Marienfeld 
Optical dishes  Glass bottom culture 
dishes (35 mm) 
MatTek 
Forceps  No 4 and No5  Neolab 
Brush  Vibratomy  Nova 
Brush  Microtomy  Roth 
ImmEdge pen  Immunostaining  Vector Lab 
 
2.3  Chemicals 
Product and supplier of the chemicals that were used in this work are listed in 
Table 2.6.  
Table 2.6: Product and supplier of used chemicals. 
Product  Supplier  Product  Supplier 
Agarose  Roth  Agar  Roth 
Agaroes (low 
melting) 
Molekula  Ampicillin  Calbiochem Materials    20 
Product  Supplier  Product  Supplier 
Blocking reagent (B 
Block) 
Roche  Bromophenol blue  Merck 
BSA  Roth  Bicine  Fluka 
BM purple AP 
substrate 
Roche  CHAPS  Sigma 
Chloroform  Roth  Collagenase Type II  Gibco 
DTT  Roth  D-Glucose  Sigma 
DNA ladder  Bioline  DEPC  Roth 
Ethidium bromide  Fisher 
Scientific 
Ethanol  Roth 
Eosin  Chroma  Formamide   Roth 
Formaldehyde (10% 
without methanol) 
Polyscience  Formalin (37% with 
10% methanol) 
Sigma 
FBS gold  PAA Lab  Glycine  Roth 
Glycerol  Sigma  Hydrochloric acid   Roth 
Hemalum  Chroma  Hydrogen peroxide  Sigma 
Heparin  Fluka  HEPES Na  Sigma 
HRP-Substrate   Thermo 
Scientific 
IPTG  Sigma 
Kanamycin  Serva  KCl  Roth 
KH2PO4  Roth  Levamisole  Fluka 
LB agar  Roth  LB medium  Roth 
Lysis buffer (10x)  Cell Signaling  MOPS buffer (20x)  NuPage  
MgCl2, 6H2O  Roth  Methanol  Roche 
Mounting  medium 
(Entellan/Xylol-
based)  
Merck  Mounting  medium 
(Kaiser’s  glycerol 
gelatin/water-based) 
Merck 
Nonidet P40  Sigma  NaN3  Sigma 
Na2HPO4  Roth  NaOH  Roth 
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Product  Supplier  Product  Supplier 
Nitrocellulose 
membrane 
Whatman  dNTPs  Invitrogen 
N-phenylthiourea  Alfa aesar  Oligo dT  Invitrogen 
PIPES  Roche  Para-formaldehyde  Sigma 
Precision Plus 
Protein Standard 
BioRad  Polyacrylamide 
precast gel 
Invitrogen 
Propanol  Roche  PMSF  Sigma 
Paraffin  Sigma  PEG-3500  Sigma 
Phenol red  Sigma  2-Propanol  Roche 
Protease  inhibitor 
cocktail 
Thermo 
Scientific 
Reverse transcriptase 
(MMLV) 
Invitrogen 
RNase inhibitor  Roche  Rhodamine phalloidin  Invitrogen 
Sodium chloride  Roth  Sodium citrate  Roth 
SDS  Fluka  Stripping buffer  NuPage  
Sodium acetate  Roth  Superscript II (RT)  Invitrogen 
Tween 20  Sigma  Triton X100  Sigma 
Tris base  Roth  Tricane  MP Biomed 
Tris base  Roth  Trizol  Invitrogen 
Whatman filter paper  Whatman  X-gal  Fluka 
Xylol  Roth  Yeast tRNA  Roche 
 
2.4  Enzymes 
The enzymes listed in Table 2.7 were used in this work. Compatible 10x buffers 
for different enzymes were supplied with the enzymes.  
Table 2.7: Product and supplier of used enzymes. 
Product  Supplier  Product  Supplier 
MMLV reverse 
transcriptase 
Invitrogen  EcoRI  NEB 
Superscript II  Invitrogen  NotI  NEB 
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Product  Supplier  Product  Supplier 
Taq DNA 
polymerase 
 
  SacII  NEB 
Top-Taq DNA 
polymerase 
Quiagen  SpeI  NEB 
T4 DNA ligase  Promega  ApeI  NEB 
SP6 RNA 
polymerase 
Roche  SacI  NEB 
T7 RNA polymerase  Roche  NdeI  NEB 
T3 RNA polymerase  Roche  XbaI  NEB 
DNase I  Roche  XhoI  NEB 
DNase II  Roche     
 
2.5  Oligonucleotides 
The  oligos  listed  in  Table  2.8  were  used  in  this  work.  All  primers  were 
purchased from Sigma-Aldrich GmbH. 
Table 2.8: Oligonucleotides used in this study. 
Oligo name  Primer sequence (5’-3’)  Gene accession 
Npnt fwd1_rat  CACAGTGCAAACACGGAGAG  XM_001075443.1 
XM_001075423.1 
Npnt rev1_rat  GCATCAGCATGTATCCGTTG  XM_001075443.1 
XM_001075423.1 
Npnt fwd2_rat  CTGGGGACAGTGTCAACCTT  XM_001075443.1  
Npnt rev2_rat  GCATCAGCATGTATCCGTTG  XM_001075443.1 
Npnt fwd1_ 
mouse 
AATCGGCCTATGTCGCTATG  NM_001029836.1 
& NM_033525.2 
Npnt rev1_ 
mouse 
GCAGCATGTATCCGTTGAGA  NM_001029836.1 
& NM_033525.2 
Primer F1_dr  CATTCGGGAGCTTCAAGTGT  NM_001145580 
Primer F2_dr  ATGTGGATCATAAAGTTCATGTTGA  NM_001145580 
Primer R_dr  CTGAAGGTCAAAGCCGTCAT  NM_001145580 Materials    23 
Oligo name  Primer sequence (5’-3’)  Gene accession 
Npnt full fwd_dr  CACCATGTGGATCATAAAGTTCATG
TTGA 
NM_001145580 
Npnt full rev_dr  TCATCCTACCGCACTCTGTTG  NM_001145580 
Npnt fwd_dr  CAATGGTCTGTGTCGGTACG  NM_001145580 
Gapdh fwd_ 
mammal 
CAGAAGACTGTGGATGGCCC  NM_017008.3 &  
NM_008084.2 
Gapdh rev_ 
mammal 
AGTGTAGCCCAGGATGCCCT  NM_017008.3 &  
NM_008084.2 
Gapdh fwd_dr  TGGGTGTCAACCATGAGAAA  NM_001115114.1 
Gapdh rev_dr  AACCTGGTGCTCCGTGTATC  NM_001115114.1 
Itga fwd  GAAAAGCCCACGGTTTACAA   NM_001114911.1 
Itga rev  TCCCCTGTGAACTCTCCAAC  NM_001114911.1 
egfra fwd  ACCGTCTGGGAGTTGATGAC   NM_194424.1 
egfra rev  TGTGTGGGACGTGTTCAGAT  NM_194424.1 
 
2.6  Antibodies 
The primary and secondary antibodies used in this study are listed in Table 2.9 
including additional information. 
Table 2.9: Antibodies used in this study. 
Primary antibody 
Antigen  Purpose/Dilution  Isotype  Supplier 
Zn8 (Alcam)  IHC 1:10   Mouse IgG1  Developmental 
Studies Hybridoma 
Bank 
Acetylated 
Tubulin 
WB 1:1000  Rabbit 
polyclonal 
Sigma 
DsRED  IHC 1:200  Rabbit 
polyclonal 
Clontech 
Pan-Actin  WB 1:1000  Rabbit 
polyclonal 
Cell Signaling 
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Primary antibody 
Antigen  Purpose/Dilution  Isotype  Supplier 
Nephronectin  WB 1:250  Rabbit 
polyclonal 
Cosmo bio lab 
Nephronectin  IHC 1:100  Rabbit 
polyclonal 
Gift from Louis F. 
Reichardt, USA 
Phospho-
Smad1/5/8 
WB 1:1000  Rabbit 
polyclonal 
Cell Signalling 
S46 (atrial 
myosin heavy 
chain) 
IHC 1:10  Mouse IgG1  Developmental 
Studies Hybridoma 
Bank 
Anti Digoxigenin-
AP conjugated  
in situ 1:5000   Fab 
fragments 
Roche 
Anti Fluorescin-
POD 
in situ 1:50   Fab 
fragments 
Roche 
       
Secondary antibody 
Antigen  Purpose/Dilution  Isotype  Supplier 
Alexa Fluor 488 
Anti-Rabbit 
ICC 1:200  goat IgG  Invitrogen 
Alexa Fluor 594 
Anti-Rabbit 
ICC 1:200  goat IgG  Invitrogen 
Alexa Fluor 488 
Anti-Mouse 
ICC 1:200  goat IgG  Invitrogen 
Alexa Fluor 594 
Anti-Mouse 
ICC 1:200  goat IgG  Invitrogen 
Alexa Fluor 646 
Anti-Mouse 
ICC 1:200  goat IgG  Invitrogen 
Anti-Rabbit IgG 
HRP-linked 
WB 1:10000  donky IgG  GE Health care UK 
limited 
Anti-Mouse IgG 
HRP-linked 
WB 1:10000  sheep IgG  GE Health care UK 
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2.7  Fish food 
Brine shrimp cysts, substitute of the brine shrimp cysts (SDS) and flakes that 
were used to feed zebrafish are listed in Table 2.10. All food was purchased 
from “Special diets services”. 
Table 2.10: List of fish food for different developmental stages of zebrafish.  
Fish age  Food 
≥ 5 dpf to < 12 dpf  SDS 100 twice/day 
≥ 12 dpf to < 1 month  SDS 100 once and artemia (brine shrimp cysts) 
twice/day 
≥ 1 month to < 2 months  SDS 200 once and artemia twice/day 
≥ 2 month to < 3 months  SDS 300 once and artemia twice/day 
Adult fish (≥ 3 months)  Mixture of flakes (Topical breeder mix) and 
SDS400 (1:1) once and artemia twice/day 
 
2.8  Buffer and solutions  
The  buffer  and  solutions  used  in  this  work  are  listed  in  Table  2.11.  Unless 
specified  otherwise  the  solutions  were  prepared  in  distilled  and  autoclaved 
water. Freshly prepared solutions for an application were not autoclaved. 
Table 2.11: Compositions of buffers and solutions. 
Buffer/Medium/Solution  Compositions 
Agarose gel loading buffer  0.25% bromophenol blue [w/v] 
0.25% xylene cyanol FF [w/v]  
15% Ficoll 400 [v/v] in dH2O 
Alkaline phosphatase (NTMT) 
buffer 
1 ml NaCl (5 M)  
510 mg MgCl2, 6H2O  
50 µl Tween 20  
5 ml Tris (1 M; pH 9.5)  
100 µl 1 M levamisole, dH2O q.s. to 50 ml 
Antigen retrivel buffer  0.1 M Tris/HCl buffer (pH 9.0) 
AEC stock  1 tablet AEC (20 mg) 
dissolve in 7.5 ml N,N dimethyl formamide 
store at -20° C Materials    26 
Buffer/Medium/Solution  Compositions 
AEC working solution  50  l AEC stock  
900  l dH2O  
100  l 0.5 M acetate buffer (pH 4.9)  
1  l H2O2 (30%)  
Acetate buffer (pH 4.9)  85 g CH3COONa, 3H2O  
900 ml dH2O 
adjust pH with glacial acetic acid 
dH2O q.s. to 1 l 
Blocking buffer (for in situ)  5% goat serum in PBS [v/v] 
B-Block  2% blocking reagent [w/v] 
10% goat serum in PBST [v/v] 
0.1% Tween 20 [v/v] 
store at -20° C
  
Conditioned water  75 g NaHCO3  
18 g sea salt  
8.4 g CaSO4  
dH2O water q.s. to 1000 l  
pH: ≈6.8-7.5, conductivity: 180-350 µS 
DEPC-Water  0.01% DEPC [v/v] in dH2O  
incubate overnight at RT and then 
autoclave for 60 min. 
DNase I solution  100 mg DNase I  
dissolve in 10 ml 10 µM MgCl2 solution, 
filter and store at -20°C 
Digestion buffer (heart tissue)  180 ml SADO mix 
90 mg pancreatin 
29 mg collagenase type II (240 U/mg) 
stir for ≈10 min and filter using a 0.22 µm 
sterile filter. 
540 µl DNase I (10 mg/ml in 10 µM MgCl2 
solution) 
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Buffer/Medium/Solution  Compositions 
Deyolking buffer  55 mM NaCl  
1.8 mM KCl  
1.25 mM NaHCO3  
dissolve in dH2O 
E3 medium  5 mM NaCl  
0.17 mM KCl  
0.33 mM CaCl2  
0.33 mM MgSO4  
0.6 µM methylene blue 
Levamisole (1 M)    241 mg levamisole in 1 ml TBST 
MOPS Buffer (10x, 1000 ml)  4.18 g 3-[N-morpholino] propanesulfonic 
acid 
680 mg sodium acetate 
2 ml 0.5 M EDTA 
dissolve in 1 l dH2O and store at 4° C in 
the dark without autoclavation (MOPS 
gets degraded) 
PBS (1x)  8 g NaCl  
0.2 g KCl  
1.44 g Na2HPO4  
0.24 g KH2PO4  
dissolve in 800 ml of dH2O, adjust pH to 
7.4 and add H2O q.s. to 1 l 
PCR buffer (10x) without MgCl2  20ml KCl (1 M)  
4ml TrisHCl (1 M), pH 9  
0.4ml Triton X100  
sterile distilled water q.s. to 40 ml 
PFA in PBS (4%)  4 g PFA dissolve in 100 ml PBS (add few 
drops of NaOH). Heat at 55° C until PFA is 
dissolved. Cool and adjust the pH to 6-7  
PBT  0.1% Tween in PBS [v/v] 
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Buffer/Medium/Solution  Compositions 
PBT/glycine  0.2% glycine in PBT [w/v] 
PT  0.3% Triton X100 in PBS [v/v] 
PBA  5% BSA [w/v] 
0.02% NaN3 [w/v] 
dissolve in PBS 
PBAT  0.3% Triton X100 in PBA [v/v] 
PBDT  0.1% DMSO and 0.1% Triton X100 in PBS 
PEM  0.1 M PIPES  
1 mM MgSO4, 7H20  
2 mM EGTA 
adjust pH to 7  
Pre-hybridization Mixture  50 ml Formamide 
25 ml 20x SSC 
1 g blocking reagent 
10.9 ml RNase free water 
dissolve at 65
°C and cool to RT 
1 ml 0.5 M EDTA 
100 µl Tween 20 
1 ml 10% CHAPS 
2 ml Heparin solution (5 mg/ml) 
10 ml Yeast tRNA (10 mg/ml)  
store at -20° C 
RIPA buffer  2.5 ml 10% SDS in water  
15 ml NaCl (5 M)   
5 ml NP40   
25 ml 10% deoxycholate in water [w/v]  
1 ml EDTA (0.5 M)       
25 ml Tris (1M, pH 8.0)   
dissolve in DEPC-treated water q.s. to  
500 ml. Don’t autoclave afterwards 
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Buffer/Medium/Solution  Compositions 
SADO mix  50 ml HEPES Na (200 mM; pH 7.6) 
50 ml NaCl (1.3 M)  
5 ml KCl (300 mM) 
5 ml NaH2PO4 (100 mM) 
1 ml glucose (2 M) 
dissolve in 390 ml dH2O 
SSC (20x)  17.53 g NaCl  
8.82 g Na citrate  
dissolve in 80 ml DEPC-treated water and 
adjust the pH to 7. DEPC-treated water 
q.s. to 100 ml 
SSC/Formamide/Tween  5 ml SSC (20x)  
25 ml formamide  
50 µl Tween 20  
DEPC-treated water q.s. to 100 ml 
TBST (10x)  8 g NaCl  
0.2 g KCl  
25 ml Tris (1 M; pH 7.5)  
1 ml Tween 20  
dH2O q.s. to 100 ml 
TAE running buffer (1x)  0.04 M Tris base 
0.002 M glacial acetic acid  
0.002 M EDTA, 2H2O  
dissolve in dH2O   
TBS  40 g NaCl  
1.8 g tris base  
dissolve in 4.5 l dH2O  
adjust the pH 7.6  
dH2O q.s. to 5 l 
TBST  0.1% Tween 20 in TBS [v/v] 
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Buffer/Medium/Solution  Compositions 
Transformation  buffer  (KCM 
buffer)  
500 mM KCl  
150 mM CaCl2  
250 mM MgCl2 
Transfer buffer (20x)  163.2 g bicine  
209.3 g bis Tris  
12 g EDTA  
dH2O q.s. to 2 l 
Transfer buffer (1x)  250 ml 20x transfer buffer  
1 l methanol 
dH2O q.s. to 5 l 
TSB buffer  10 g PEG-3500  
5 ml DMSO  
1 ml 1 M MgCl2  
1 ml 1 M MgSO4  
LB medium (pH 6.1) q.s. to 100 ml 
sterilize by passing through 0.45 µm filter 
and store at 4° C 
Wash buffer  110 mM NaCl  
3.5 mM KCl  
2.7 mM CaCl2  
500 µl 1 M  
Tris HCl (pH 8.5) 
dH2O q.s. to 50 ml 
 
2.9  Kits  
The kits that were used in this work are listed in Table 2.12. 
Table 2.12: List of kits used in this study. 
Kit  Purpose  Supplier 
Agarose gel extraction kit  cDNA isolation  QIAGEN 
Avidin/Biotin Blocking kit  Block nonspecific binding of 
Biotin/Avidin for enzymatic 
immunostaining 
Vector Lab Materials    31 
Kit  Purpose  Supplier 
ABC solution kit  Enzymatic immunostaining  Vector Lab 
PCR purification kit  PCR product cleanup  QIAGEN 
QIAprep spin Miniprep  Plasmid extraction  QIAGEN 
QIAprep spin Midiprep  Plasmid extraction  QIAGEN 
RNA easy  RNA isolation  QIAGEN 
mMessage Machine   In vitro capped mRNA 
synthesis 
Ambion 
DIG RNA labeling kit 
(SP6/T7) 
In situ probe synthesis  Roche 
Bio-Rad Dc protein assay kit  Protein concentration  BIO-RAD 
SuperSignal West Femto 
substrate 
Chemiluminescence  Thermo 
Scientific 
 
2.10  Antibiotics 
Antibiotics that were used in this study are listed in Table 2.13. Ampicilin and 
kanamycin were stored at 4ºC. Chloramphenicol and tetracyclin were stored at 
-20ºC and Gentamycin was stored at RT. 
Table 2.13: Antibiotics and their working concentrations. 
Antibiotics  Working concentration 
Liquid culture  Agar plates  
Ampicilin   100  g/ml  100  g/ml 
Chloramphenicol   15  g/ml   30  g/ml 
Kanamycin   20  g/ml   20  g/ml 
Gentamycin   10  g/ml    7  g/ml 
Tetracycline   10  g/ml   10  g/ml 
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2.11  Zebrafish lines  
Different zebrafish lines used in this work are listed in Table 2.14. 
Table 2.14: List of zebrafish lines and their specification. 
Fish line  Reference  Specification 
AB line    Wild type 
Tg(myl7:EGFP-HsHRAS)
s883  (95)  EGFP is localized in the plasma 
membrane of cardiomyocytes.  
Tg(kdrl:EGFP)
s843  (96)  EGFP is expressed in endothelial 
cells. 
Tg(-5.1myl7:nDsRed2)f2  (97)  DsRed is localized in the nuclei of 
cardiomyocytes. 
Tg(TOP:GFP)
w25  (98)  EGFP is expressed under control 
of the promoter region containing 
4 consensus LEF binding sites. 
Tg(hsp70l:dkk1-GFP)
w32  (99)  dkk1 is expressed under the 
control of the heat shock protein 
70 promoter. 
 
2.12  Plasmids  
Different constructs were used for in situ probe synthesis in this work. Gene 
name, construct backbone and restriction enzymes are listed in Table 2.15. 
Table 2.15: List of plasmids for in situ probe synthesis, restriction enzymes and 
respective RNA polymerases. 
Gene 
name 
Vector  Resistance 
to 
Enzyme  RNA 
polymerase 
Type of 
probe 
amhc  pSPORT1  Ampicillin  EcoRI  SP6  Antisense 
amhc  pSPORT1  Ampicillin  BamHI  T7  Sense 
fbln1  Unknown  Ampicillin  XhoI  T7  Antisense 
bmp4  pCS2+  Ampicillin  BamHI  T3  Antisense 
vmhc  pGEMT- Easy  Ampicillin  NotI  T7  Antisense 
vmhc  pGEMT- Easy  Ampicillin  SacII  SP6  Sense 
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Gene 
name 
Vector  Resistance 
to 
Enzyme  RNA 
polymerase 
Type of 
probe 
cspg2  pBluescript  II 
SK(+) 
Ampicillin  NotI  T7  Antisense 
npnt  pGEMT-Easy  Ampicillin  SacII  SP6  Antisense 
npnt  pGEMT-Easy  Ampicillin  SpeI  T7  Sense 
notch1b  pBluescript 
SK(+) 
Ampicillin  BamHI  T3  Antisense 
notch1b  pBluescript 
SK(+) 
Ampicillin  SacII  T7  Sense 
nppa  Unknown  Ampicillin  NotI  SP6  Antisense 
has2  pBSK  Ampicillin  XbaI  T7  Antisense 
tbx2b  pBS II SK  Ampicillin  BamHI  T7  Antisense 
eGFP  pCS2+  Ampicillin  EcoRI  T7  Antisense 
eGFP  pCS2+  Ampicillin  XhoI  SP6  Sense 
 
2.13  Morpholino oligonucleotides  
Morpholinos were purchased from Gene Tools and dissolved in sterile water as 
1 mM stock solution (Table 2.16). 
Table 2.16: List of morpholinos, their target sites and sequences. 
Morpholino   Target  Sequence (5’-3’) 
MO1  Translation inhibitory 
morpholino against npnt  
CATGAACTTTATGATCCACA
TCTCC 
MO2  Splicing inhibitory morpholino 
against npnt  
TGTGAAACGGCAGACGGAA
CTCACT 
MO3  Splicing inhibitory morpholino 
against npnt  
GAATAGGCTAAGTGCCGTC
TCACCT 
Has2-MO  Translation inhibitory 
morpholino against has2 
AGCAGCTCTTTGGAGATGT
CCCGTT 
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2.14  Growth media 
Different media used for bacterial, cardiomyocyte and non-myocyte culture in 
this work are listed in Table 2.17.  
Table 2.17: Name, purpose and formulation of used media. 
Media  Purpose  Formulation 
Neonetal medium  Cardiomyocyte isolation 
from neonatal rat heart 
DMEM/F-12 medium 
supplemented with: 
Na-pyruvate (3 mM) 
L-glutamin (2 mM) 
ascorbic acid (0.1 mM) 
insulin/transferin/Na 
selenite (1:100) 
BSA (0.2%) 
penicillin (100 U/ml) 
streptomycin (100 
mg/ml) 
Preplating medium   Non-myocyte separation 
from harvested cells from 
neonatal rat heart 
DMEM/F-12 medium 
supplimented with 
FBS (10%) 
L-glutamin (2 mM) 
penicillin (100 U/ml) 
streptomycin (100 
mg/ml) 
LB agar  Propagation of bacteria  35 g in 1 l H2O 
LB medium  Propagation of bacteria  20 g in 1 l H2O 
SOC medium  Bacterial transformation   Ready made from Sigma 
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2.15  Competent cells 
Different competent bacterial strains were used for transformation (Table 2.18). 
Table 2.18: Bacteria used as competent cells for plasmid propagation. 
Bacterial Strain  Specification 
XL1-Blue  Competent cells  
Dh5α  Competent cells  
 
2.16  Software 
Software used for data analysis in this study is listed in Table 2.19. 
Table 2.19: Software used in this study and its application. 
Software  Application 
Microsoft Office Excel, Word, 
Powerpoint 
Data anlysis and Documentation 
Adobe Photoshop, Illustrator, Reader  Figure preparation 
Image J  Image analysis 
LSM Image Browser  Confocal Image analysis 
GraphPad Prism  Graphical representation and 
statistical analysis 
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3.  Methods 
3.1  Zebrafish maintenance 
Wild type AB and transgenic zebrafish (Danio rerio) are in general maintained 
at 28°C as described (100). For this study zebrafish were maintained in a state-
of-the-art  zebrafish  housing  system  by  Tecniplast  (Tecniplast  Deutschland 
GmbH) using conditioned water (Figure 3.1).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.1:  Scheme of the  used  zebrafish housing  system.  Arrows indicate direction  of 
water flow. 
Water temperature was maintained at 26-28° C and air temperature at 
27-29° C. In this system 10-20% of the water in each fish tank is exchanged per 
day as zebrafish waste contains ammonium compounds, which are highly toxic. 
In  addition,  biological  filters  were  used  to  detoxify  the  water.  The  biological 
filters  provide  a  large  surface  area  to  grow  denitrifying  aerobic  bacteria  like 
Nitrosomonas and Nitrobactor, which degrade ammonium compounds to nitrite. 
Other  mechanical  filters  plus  pH  adjustment,  conductivity  adjustment,  and  a 
sterilization unit were connected in a series to maintain the properties of the 
conditioned water. 
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3.2  RNA isolation and reverse transcription (RT) 
RNA was extracted from zebrafish embryos (30 to 50) and from rat or mouse 
heart ventricles (fetal: >20; postnatal: 3 to 5) at different developmental stages 
using  Trizol  reagent  according  to  manufacturer’s  instructions  with  minor 
modifications. To homogenize ≤ 1 g of tissue 1 ml of Trizol reagent was used. 
Isolated RNA  was  dissolved  in  30 to  50 µl RNase  free  water and stored at 
-80° C. 
cDNA  was prepared from isolated RNA using  MMLV or superscript II 
reverse transcriptase. For MMLV-mediated reverse transcription 1 µg RNA was 
incubated with 1 µl dNTP mix (10 mM), 0.5 µg oligo dT and RNase free water 
q.s. to 10 µl at 65° C for 5 min. Then this reaction mixture was incubated with 
2 µl MMLV reverse transcriptase buffer (10x), 7 µl RNase free water and 1 µl 
MMLV reverse transcriptase at 37° C for 50 min. After 50 min the incubation 
reaction was inactivated by incubation at 80°C for 10 min and RNase free water 
was added q.s. to 100 µl. Synthesized cDNA was stored at -80° C
 for further 
use.  
 
3.3  cDNA amplification by PCR 
For PCR-mediated cDNA amplification, a standard PCR reaction was set up. 
As a template for the reaction 1 µl cDNA was used. A master mix was prepared 
by  adding  10  pmol  forward  and  reverse  primers,  10  nmol  dNTPs,  40  nmol 
MgCl2, 0.5 U Taq polymerase and 1x PCR amplification buffer (MgCl2 free). 
The  amplification  was  carried  out  in  a  GeneAmp  PCR  System  9700 
thermocycler  from  Applied  Biosystems  under  the  following  conditions:  initial 
denaturation for 2-5 min at 94° C; 24-35 cycles of 30 sec at 94° C, annealing at 
58° C to 60° C and extension of 1 min per 1 kb of product size at 72° C. After the 
last cycle the reaction was held for 7 min at the extension temperature to allow 
the completion of amplification of all products. Subsequently, the temperature 
was lowered to 4°C to stop the reaction. 
 
3.4  Agarose gel electrophoresis 
The  cDNA  was  resolved  on  1.5-2%  agarose  gels  prepared  in  TAE  buffer 
containing  EtBr.  The  electrophoresis  was  run  for  30  to  60  min  in  TAE Methods    38 
depending  upon  PCR  product  size.  cDNA  was  visualized  under  UV  light, 
λ=260 nm. 
 
3.5  cDNA elution from agarose gel 
Resolved PCR products were purified from agarose gel using the QIAquick gel 
extraction  kit  according  to  manufacturer’s  instructions  (QIAGEN)  and  eluted 
with 30 µl nuclease free water.  
 
3.6  Cloning 
To generate different constructs cDNA was synthesized from mRNA extracted 
from  52  hpf  embryos.  cDNA  was  amplified  with  the  help  of  PCR  using 
appropriate primer pairs and TopTaq DNA polymerase (Qiagen). To clone the 
full  length  coding  sequence  of  npnt  contaning  its  partial  3’UTR  region,  a 
1945 bp fragment of zebrafish npnt cDNA (NM_001145580) was amplified with 
the primer pair Npnt full fwd_dr and Npnt full rev_dr. To make a construct for in 
situ  probe  generation  against  npnt,  integrin  α8  (itga8)  and  EGF  receptor  a 
(egfra) mRNA, a 517 bp (primer pair: Npnt fwd_dr, Primer R), a 713 bp (primer 
pair: Itga fwd and Itga rev) and a 729 bp cDNA fragment (primer pair: egfra fwd 
and egfra rev) was amplified. All amplified cDNAs were resolved by agarose 
gel electrophoresis and eluted from the gel. 
TopTaq has 5'–3' exonuclease activity but no 3'–5' exonuclease activity 
and this enzyme leaves an “A” overhang at the 3’ end. To make sticky end 
ligation  pGEMT  easy  vector  (Promega)  was  used  which  carries  a 
complementary “T” overhang. 
Purified cDNA was ligated into the pGEMT easy vector by incubating a 
mixture of 5 µl rapid ligation buffer (2x), 3 µl eluted cDNA, 1 µl pGEMT easy 
vector  and  1  µl  T4  DNA  ligase  (joins  between  the  5’-phosphate  and  the 
3′-hydroxyl groups) at 4° C
 overnight. Full length npnt cDNA was subcloned into 
the pCS2+ vector after EcoR1 double digestion, with the help of T4 DNA ligase 
(RZPD, pCS2+-Fnpnt), and was subsequently sequenced. 
   
3.7  Preparation of competent E.coli cells 
A single colony of E. coli strain (DH5α or XL1Blue) was inoculated in 5-6 ml LB 
medium and cultured overnight at 37° C with shaking. 4 ml of grown culture was Methods    39 
added into fresh 250 ml LB and grown to early logarithmic phase (OD600=0.3-
0.6). The culture was centrifuged for 5 min at 2500 rpm at 4° C in a table top 
centrifuge.  The  bacterial  pellet  was  resuspended  in  25  ml  cold  TSB  buffer 
(1/10
th volume of the bacterial suspension) and incubated on ice for 10 min. 
Competent cell suspension was aliquoted into cold eppendorf tubes (100 µl and 
200 µl) and snap frozen in liquid nitrogen. Aliquoted frozen competent bacterial 
cells were stored at -80° C. 
 
 3.8  Transformation of E. coli competent cells 
Part of a ligation reaction mixture (5 µl) or 1-10 ng of plasmid DNA was added 
to  20   l  of  5  ×  KCM  buffer;  water  was  added  q.s.  to  100   l  in  a  1.5  ml 
eppendorf tube. An equal volume of thawed competent cells was added to the 
reaction mixture and mixed by flicking. The reaction mixture was incubated on 
ice for 20 min followed by incubation at RT for 10 min. Then 1 ml of LB medium 
(without any antibiotic) was added to the mixture and incubated for 1h at 37° C 
with vigorous shaking. Finally cells were plated on LB Agar plates containing 
appropriate antibiotic. Plates were incubated at 37° C overnight. 
 
3.9  Plasmid DNA isolation  
The “mini-prep” method is useful for preparing partially purified plasmid DNA in 
small quantities from a number of transformants. It is based on the alkaline 
lysis method using SDS (101). A single colony was selected and inoculated in 3 
to 5 ml of LB medium containing the appropriate antibiotic with a sterile pipette 
tip. Bacterial cells were cultured overnight at 37°C with vigorous shaking. The 
cells  were  harvested  by centrifugation for  4  min at 4000  rpm in  a table  top 
centrifuge (Eppendorf 5415C). Plasmid DNA was isolated using the QIAGEN 
miniprep kit following the manufacturer’s instructions. At last plasmid DNA was 
extracted  from  the  affinity  column  with  30  µl  sterile  water.  Large  amount  of 
plasmid DNA was prepared using the QIAGEN Plasmid Midi Kit according to 
the manufacturer’s instructions. 
 
3.10  Determination of the concentration of nucleic acids  
The  DNA  and  RNA  concentrations  in  solution  were  estimated  using  a 
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was measured at 260 nm and the concentration of nucleic acids was calculated 
by  the  manufacturers  software  based  on  the  Beer-Lambert  Law  (Aλ  =εbc). 
Where  Aλ  is  the  absorbance  (Aλ  =  log10  P0  /  P),  ε  is  the  molar  absorbtivity 
(molar extinction coefficient), b is the path length of the sample and c is the 
concentration of the compound in solution.  
The molar absorbtivity of double stranded DNA is ε = 50 cm
-1 M
-1, for 
single stranded DNA is ε = 33 cm
-1 M
-1, and for RNA is ε = 40 cm
-1 M
-1. 
 
3.11  In situ hybridization 
3.11.1 Probe synthesis 
In situ constructs were linearized with proper restriction enzymes (Table 2.10) 
and used as template for probe synthesis. Reaction mixtures containing 1 µg 
linearized plasmid (13 µl final volume), 2 µl 10x NTP labeling mixture, 2 µl 10x 
transcription buffer, 1 µl protector RNase inhibitor and 2 µl RNA polymerase 
(SP6/T7/T3) were incubated at 37° C
 for 2 h (Table 2.10). After probe synthesis 
the DNA template was digested by incubation for 30 min at 37°C
 after adding 
2.5  µl  DNase  buffer  (10x)  and  2.5  µl  DNase  I.  The  synthesized  probe  was 
precipitated by adding 2.5 µl 0.2 M EDTA, 2.5 µl 5 M LiCl and 93 µl ethanol and 
incubation at -80° C
 for 40 min. After centrifugation at 17000 x g for 10 min at 
4° C
 the supernatant  was  removed  and  the  pelleted  probe  was  washed  with 
200 µl 70% ethanol (kept at -20° C
 for 15 min) and again centrifuged (10 min, 
17000 x g, 4° C
 ). Subsequently, the supernatant was removed and the probe 
was air dried. Finally, the probe was dissolved in 40 µl water and 1 µl RNase 
inhibitor (final con. 1 U/µl) and stored at -80° C for further use. 
 
3.11.2 Fixation and storage of embryos 
Embryos were fixed with 4% PFA (paraformaldehyde) overnight or up to 3 days 
at 4° C. Embryos younger than 24 hpf were fixed with chorion and decorinated 
after  fixation.  Older  embryos  were  fixed  after  dechorination.  Fixed  embryos 
were  washed  twice  with  PBST  for  30  min  at  RT.  Washed  embryos  were 
dehydrated with a series of methanol:PBT solutions (25:75, 50:50, 75:25) and 
twice with 100% methanol (10 min each step at 4° C). Then embryos were used 
directly for in situ or stored in methanol at -20° C
 for later use. 
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3.11.3 1
st day-hybridization 
Embryos were rehydrated through a series of methanol:PBT solutions (75:25, 
50:50, 25:75), and washed twice with PBT (10 min each step at 4° C
 ). Older 
than 40  hpf embryos  were bleached  with 6% hydrogen peroxide  in PBT for 
30 min at 4° C
 and washed thrice with PBT for 5 min. Washed embryos were 
treated with proteinase K (10 µg/ml) as follows: 
•  Up to 26+ somite stage (22 hpf) 30 sec to 1 min digestion at RT 
•  Prim 5 to prim 15 (24 hpf to 30 hpf) 10 min digestion at RT 
•  Prim 15 to Pec fin (36 hpf to 60 hpf) 25 min digestion at RT 
•  Protruding mouth (>72 hpf) 30 min digestion in RT 
Proteinase  K  was  inactivated  by  washing  twice  with  PBT  buffer  containing 
glycine (2 mg/ml) and thrice with PBT. Embryos older than 20 hpf were washed 
twice with RIPA buffer and then washed thrice with PBT. Embryos of all stages 
were  fixed  for  20  min  at  RT  with  PBT  containing  4%  PFA  and  0.2% 
glutaraldehyde.  Fixed  embryos  were  washed  thrice  with  PBT,  with 
prehybridization buffer for 10 min and then incubated in prehybridization buffer 
for 2 h at 70°C
. DIG-labeled probes were diluted in hybridization buffer (1 µg/ml) 
and  denatured  by  heating at 100° C on a heating block for 5 min. After 2 h 
incubation in prehybridization buffer embryos were incubated overnight at 70° C
 
in hybridization buffer having denatured probe. 
 
3.11.4 2
nd day-unbound probe removal 
Hybridized  embryos  were  washed  twice  with  prehybridization  buffer  (30  min 
each,  65° C),  once  with  a  mixture  of  prehybridization  buffer:SSC/ 
Formamide/Tween 20 (1:1) (10 min, 65° C), five times with SSC/Formamide/ 
Tween  20  (20  min  each,  65° C),  with  the  mixture  of  TBST:SSC/Formamide/ 
Tween  20  (1:1)  (10  min,  RT),  and  then  washed  thrice  with  TBST  at  RT. 
Embryos were incubated in blocking solution for 1 h at RT. At the same time 
anti-DIG antibody was incubated in blocking solution (antibody dilution-1:5000) 
at RT. After blocking embryos were incubated with antibody solution at 4° C for 
overnight.  
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3.11.5 3
rd day-unbound antibody removal and staining 
Antibody solution was removed and embryos were washed with TBST at RT 
twice for 5 min, twice for 15 min and thrice for 30 min. Subsequently, embryos 
were washed thrice with NTM-T buffer (alkaline phosphatase buffer) at RT for 
20 min and incubated in staining solution (BM purple, Roche) in the dark at RT. 
The incubation time depended on the probe and took a few hours up to several 
days. For longer incubation embryos were incubated at 4° C on a belly dancer 
shaker. Staining was stopped by washing in dH2O or dH2O containing 0.1% 
Tween 20. For cleaning the embryos were washed twice with 100% ethanol for 
15 min, then washed with 50% ethanol and at last with PBT. For whole-mount 
photography embryos were washed in ddH2O and stored in 50% glycerol. 
 
3.12  Embedding and documentation 
Cleaned whole-mount embryos were fixed in 4% PFA in PBS overnight at 4° C
 
and then embedded in 17% gelatin in PBS. Gelatin was dissolved in PBS by 
boiling and solution temperature was adjusted to 50-60°C before embedding. 
Embedding  was  done  on  plastic  moulds.  and  Gelatin  polymerization  was 
achived  by  incubation  on  ice.  Polymerized  gelatin  blocks  were  fixed  by 
incubating in 4% PFA overnight at RT. 100 µm thick sections were made by 
vibratome  at  RT  and  mounted  on  glass  slides  using  water  based  mounting 
medium (Kaiser’s glycerol gelatin, Merck) for microscopy.  
 
3.13  Capped npnt mRNA synthesis 
3.13.1 Linearized template generation 
Capped npnt mRNA was generated using a “mMESSAGE mMACHINE SP6” in 
vitro  transcription  kit.  pCS2+-Fnpnt  plasmid  was  linearized  by  overnight 
restriction digestion with SacII at 37° C [reaction mixture: 5 µg plasmid + 5 µl 
10x BSA + 5 µl 10x buffer 2 + 8 U SacII + nuclease free water q.s. to 50 µl]. 
Restriction digestion was stopped by adding 5 µl (1/10th volume) ammonium 
acetate reaction stop buffer, 2.5 µl 0.5 M EDTA (1/20th volume) and 100 µl (2 
volume) ethanol to the digestion mixture and incubation at -20° C for 15 min. 
This  mixture  was  then  centrifuged  at  17000  x  g  for  15  min  at  4° C  and  the 
pelleted linearized plasmid was resuspended in 10 µl RNase free water.  
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3.13.2 In vitro capped RNA synthesis 
To  synthesize  capped  npnt  mRNA,  1  µg  of  linearized  template  DNA  was 
incubated in the mixture of 10 µl 2x NTP/CAP mix, 2 µl enzyme mix, 2 µl 10x 
reaction buffer and nuclease free water q.s. to 20 µl at 37° C for 2 h. Later on 
template DNA was denatured by incubating the reaction mixture with 1 µl Turbo 
DNase at 37° C for 15 min. Synthesized capped npnt mRNA was purified by 
LiCl  precipitation.  For  this,  reaction  mixture  was  mixed  with  30  µl  LiCl 
precipitation solution and 30 µl nuclease free water and incubated for 30 min at 
-20° C, followed by centrifugation at 17000 x g for 15 min at 4° C. Capped npnt 
mRNA pellet was washed with 1 ml 70% nuclease free ethanol and centrifuged 
at 17000 x g for 15 min at 4° C. After removing the supernatant the pellet was 
air-dried and dissolved in 20 µl nuclease free water. To inhibit RNA degradation 
a  RNase  inhibitor  was  added  to  the  capped  RNA  solution  (1  U/µl  final 
concentration) and stored at -80° C for further use. 
 
3.14  Manipulation of gene expression 
Gene expression was manipulated by injection of morpholino oligonucleotides 
or capped mRNA with the help of a microinjector. For knockdown studies single 
cell  stage  embryos  were  injected  with  different  amounts  of  morpholino 
oligonucleotides  (≤  4  nl).  Four  different  morpholino  oligonucleotides  (MOs) 
were used for this study (Table 2.16). For rescue experiments single cell stage 
embryos  were  injected  with  different  amounts  of  capped  npnt  mRNA  alone 
(control) or together with MO2. The total volume of injected solution was ≤ 4 nl. 
Capped npnt mRNA was dissolved in sterile and RNase free 0.1M KCl solution. 
Phenol red was added (0.05%) to injected solutions.  
 
3.15  BMP signaling inhibition 
Dorsomorphin,  a chemical antagonist  of BMP  receptors,  was used  to inhibit 
BMP signaling (102). Different concentrations of dorsomorphin (2 µM, 5 µM, 10 
µM or 50 µM) were added to MO2-injected or wild type embryos at 25 hpf in E3 
medium  to  inhibit  BMP  signaling.  Dorsomorphin  has  shown  its  maximum 
inhibitory effect on Smad phosphorylation and a concentration of 10 µM and 
this  concentration  was  used  for  BMP  signaling  inhibition  studies.  Cardiac 
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were  analysed  by  immunostaining  and  in  situ  hybridization  techniques  at 
52 hpf. 
 
3.16  Protein extraction from whole zebrafish embryos 
Protein was extracted from 50 to 60 pooled embryos at 52 hpf for Npnt knock 
down and at 48 hpf for BMP signaling inhibition study. At first the yolk was 
removed by shearing (pipetting) and shaking in deyolking  buffer (2 x 3 min, 
1100 rpm) and then washed by shaking (3 min, 1100 rpm, on a MHL20 shaker) 
with washing buffer. Washed embryos were pelleted by centrifugation (300 x g, 
1  min  at  4° C)  and  supernatant  was  removed.  Pelleted  embryos  were 
homogenized with Precellys 24-Dual homogenizer (Peqlab) in a lysis mixture 
containing  lysis  buffer  from  Cell  Signaling,  protease  inhibitor  mix  (Thermo 
Scientific) and 1 mM PMSF. Homogenized tissue was centrifuged for 10 min at 
10000 x g and 4°C. Supernatants were collected in 1.5 ml Eppendorf tubes and 
stored at -80°C for further experiments. 
 
3.17   Determination of protein concentration 
Protein concentration was estimated using the BioRad DC Protein Assay Kit 
which is based on the Lowry method (103). Five  l protein extract was mixed 
with 5  l water, 20  l reagent A and 200  l reagent B and incubated for 15 min 
at  RT.  Absorbance  of  the  solution  was  measured  by  a  microplate  reader 
(spectrophotometer  from Tecan)  at  λ=720  nm. Protein sample  concentration 
was calculated by the manufacturer’s software based on a standard curve that 
was determined using BSA standards. 
 
3.18  Western blot analysis 
Cell  lysates  or  tissue  extracts  were  resolved  by  a  gradient  (4-12%)  SDS-
polyacrylamide gel (104). Lysates or extracts were mixed with reducing reagent 
and NuPage loading dye from Invitrogen and were incubated at 95°C
 for 5 min. 
Samples containing 15-25 µg protein were loaded on NuPAGE 4-12% Novex 
Bis-Tris Gels (Invitrogen) and resolved by electrophoresis for 30 min at 75 V 
followed  by  1.30  to  2  h  at  150  V  at  4° C.  Resolved  protein  samples  were 
transferred to a nitrocellulose membrane by electrophoresis at 20 W for 1 h at 
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blocking solution (5% bovine albumine or 5% skimmed milk in TBST) for 1 h at 
RT.  The  blots  were  then  incubated  with  rabbit  polyclonal  anti-Npnt  antibody 
(1:250 in 5% skimmed milk/TBST), mouse anti-pan-Actin antibody (1:1000 in 
5% bovine albumin/TBST), rabbit anti phospho-Smad 1/5/8 antibody (1:1000 in 
5%  bovine  albumin/TBST),  or  rabbit  monoclonal  anti-acetylated  tubulin 
antibody (1:1000 in 5% Bovine albumin/TBST) at 4° C overnight under shaking. 
After overnight incubation blots were washed thrice with TBST for 5 min at RT 
and then incubated for 1 h with HRP conjugated secondary antibody in blocking 
buffer (1: 6000) at RT. After incubation blots were washed thrice with TBST for 
5 min at RT. The bound antibodies were detected by incubating the membrane 
with a 1:1 mixture of a chemiluminescent substrate and an enhancer solution 
from  Thermo  Scientific  (Super  signal)  and  chemiluminescence  was 
documented  by  a  blot  developing  system  from  FujiFilm,  which  can  detect 
chemiluminescence. 
 
3.19  Histological analysis 
Hematoxylin/eosin  staining  was  performed  for  morphometric  analyses. 
Zebrafish, mouse or rat embryos were fixed in 4% PFA/PBS at 4°C overnight. 
Fixed embryos were dehydrated by incubating them in series of ethanol:water 
mixtures (50:50, 70:30, 80:20, 90:10, 96:04) and twice with 100% ethanol (for 
zebrafish:  1  h  each  step  at  RT  and  for  mouse/rat  2  h  each  step  at  RT). 
Dehydrated embryos were washed with butanol overnight at RT and then twice 
with  paraffin  (at  least  2-3  h  each  step  at  65° C).  Washed  embryos  were 
embedded  in  parraffin  and  sectioned  with  a  microtome  (7  µm  thick)  and 
mounted on glass slides after stretching them by putting them in a 55° C water 
bath. After mounting, glass slides were incubated at 37° C overnight and stored 
at  RT  for  further  experiments.  Mounted  sections  were  deparaffinised  by 
washing  thrice  with  xylol  (7  min  each  step),  twice  with  100%  ethanol  (2min 
each  step)  and  then  series  of  ethanol:  water  mixtures  (96:4,  90:10,  70:30, 
50:50) for 1 min each step. At last sections were washed with tap water at least 
for  5  min.  For  staining  rehydrated  mounted  sections  were  incubated  in 
Hemalum for 10 min and washed with warm running tap water until sections 
became  blue.  Sections  were  rinsed  with  distilled  water  for  1-2  min.  After 
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shortly washed once with 95% ethanol and once with 100% ethanol. At last 
sections were put into xylol and mounted with xylol-based mounting medium 
(Entellan, Merck). Mounted samples were analysed by bright field microscopy. 
 
3.20  Immunohistochemistry 
Zebrafish immunohistochemistry was performed as previously described (81). 
Around 30 embryos were washed shortly (not > 30 sec) with PT. For Alcam 
staining  embryos  were  fixed  for  4  h  in  4%  methanol-free  formaldehyde 
(Polyscience)  in  PEM  at  RT.  Samples  were  washed  thrice  with  PBS  and 
incubated in PBA for 1h at RT. After blocking, embryos were incubated with 
mouse  monoclonal  anti-Alcam  (zn8)  antibody  (1:10  in  PBA)  for  overnight  at 
4° C. Subsequently, samples were washed thrice with PBS and incubated with 
anti-mouse  antibody  conjugated  with  ALEXA  fluochrome  for  2  h  at  RT.  For 
atrial myosin heavy chain and DsRed staining embryos were fixed for overnight 
in 1% methanol-free formaldehyde (Polyscience) in PEM at 4° C. Samples were 
washed thrice with PBS and incubated in PBA for 1h at 4° C. After blocking, 
embryos were incubated with mouse monoclonal anti-atrial myosin heavy chain 
(s46)  (1:10  in  PBA)  and/or  rabbit  polyclonal  anti-DsRed  antibody  (1:200  in 
PBA)  for  overnight  at  4° C.  Subsequently,  samples  were  washed  thrice  with 
PBS and incubated with anti-mouse and/or anti-rabbit antibody conjugated with 
different  ALEXA  flurochrome  overnight  at  4° C.  After  staining  samples  were 
washed thrice with PBS and incubated in 4% PFA for 1-2 h at RT. For F-Actin 
staining samples were incubated with rhodamine-labeled phalloidin (1:75, 1 h, 
RT) in PBDT. Whole mount embryos were used for confocal microscopy after 
embedding in 1.5% (w/v) low melting agarose gel in PBS. 
For  immunohistochemistry  of  rat  tissue,  rat  embryos  (E14)  were 
processed for paraffin sectioning and 6 µm thick sections were mounted on 
slides. Sections were deparaffinised by washing thrice with Xylol for 7 min, with 
100% ethanol for 2 min, 96%, 90%, 70% and 50% ethanol for 1 min and at last 
with  warm  tap  water  (at  least  for  5  min).  Before  immunostaining  antigen 
retrieval  was  performed  by  incubating  the  slides  in  0.1M  Tris/HCl  buffer 
(pH 9.0) overnight at 80° C
. After cooling down the slides were rinsed thrice with 
PBS for 5 min. Each tissue section was circumscribed with an ImmEdge pen. 
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solution  for  15  min  at  RT  and  washed  once  with  PBS.  Subsequently 
endogenous biotin  was blocked by incubating the tissue sections  with biotin 
solution for 15 min at RT and washed once with PBS. Tissue sections were 
blocked  by  incubating  with  5%  goat  serum  in  PBS  for  1  h  at  RT.  Blocked 
sections  were  incubated  in  blocking  buffer  containing  rabbit  polyclonal  Npnt 
antibody (1:100) and for negative control sections were incubated with blocking 
buffer overnight at 4° C in a humidified chamber. Samples were washed thrice 
with PBS and subsequently incubated in 0.1% H2O2 in PBS for 10 min at dark 
to  block  endogenous  peroxidase.  To  stop  the  H2O2  reaction  samples  were 
washed  thrice  with  PBS.  Subsequently,  samples  were  incubated  with  biotin 
conjugated antirabbit antibody (secondary antibody) in PBS (1:100) for 45 min 
at RT. ABC solution mixture was prepared by adding 1 µl of each solution from 
ABC kit in 100 µl PBS and incubated for 30 min before adding on sections. 
Secondary  antibody  was  washed  away  by  rinsing  thrice  with  PBS. 
Subsequently sections were incubated with ABC solution for 30 min at RT and 
washed  thrice  with  PBS.  AEC  substrate  was  prepared  according  to  the 
manufacturer instructions and sections were incubated with AEC substrate for 
15 min at RT. After these slides were rinsed with dH2O for three times they 
were incubated in Hematoxylin for 30 sec. Excess Hematoxylin was removed 
by rinsing the slides with running tap water for 3 min and washed sections were 
mounted  with  Kaisers glycerin  (water  based mounting medium). All washing 
steps lasted 5 min. Washing and Hematoxylin incubation was done using glass 
slide holder. 
 
3.21  Isolation of neonatal rat heart cells 
Neonatal rats (P3) were decapitated, the chest  was opend  and hearts were 
removed  with  a  curved  forcep.  Isolated  hearts  (10  to  20)  were  placed  in  a 
petridish 20 ml PBS without Ca
2+ and Mg
2+ containing 5 mM glucose in on ice. 
Using a scalpel blade, the aorta and the atria were removed. The remaining 
ventricles were gently squeezed with forceps to remove the blood and washed 
with PBS without Ca
2+ and Mg
2+ containing 5 mM glucose. 
  The ventricles were placed on a dry petridish and were minced as small 
as possible using a scalpel blade. The minced heart tissue was transferred to a 
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bar, in a 37° C water bath on a magnetic stirrer (200 to 300 rpm). After 3 min the 
corex glass tube was removed that the tissue could settle on the bootom (3 min 
tissue sedimentation). Subsequently the supernatant was discarded. This wash 
step  was  followed  by  a  series  of  digestion  steps  each  with  10  ml  digestion 
buffer. The first two digestion steps involved 10 minutes of digestion followed 
by 5 min sedimentation. This procedure was continued with 8 min digestion and 
5  min  sedimentation  for  5  steps  more.  After  each  sedimentation  step,  the 
supernatant containing the cells was collected and transferred to 50 ml falcon 
tube  containing  4  ml  ice-cold  horse  serum  (each  tube  to  collect  40  ml 
supernatant) and kept on ice. The tubes containing the cell suspension in horse 
serum  were  centrifuged  at  330  x  g  for  3  minutes  at  4° C.  Subsequently  the 
supernatant was discarded and the cell pellets were resuspended in preheated 
preplating  medium  (37° C,  10  ml  per  5  hearts).  The  cell  suspension  was 
preplated  on  10  cm  cell  culture  dishes  (10  ml  cell  suspension/dish)  and 
incubated for 1h 30 min at 37° C at 5% CO2 level. During this preplating, non-
myocytes attach to the cell culture dish whereas cardiomyocytes get enriched 
in the medium.  
  The supernatant from the preplating step was collected in 50 ml falcon 
tubes. Cells were pelleted at 330 x g for 3 min at 4° C and RNA was isolated 
from the cell pellet (cardiomyocytes) or from the attached non-myocytes after 
washing  twice  with  PBS  using  the  QIAGEN  RNA  easy  kit  according  to 
manufacturer’s instructions. 
 
3.22  Microscopy and morphological analysis 
For  the  Nomarski  (Zeiss)  and  confocal  imaging  of  live  fish  hearts,  embryos 
were anesthetized with 0.02% tricane in E3 medium and mounted with 1.5% 
low  melting  agarose  in  E3  medium.  For  immunohistochemistry  fixed  whole-
mount embryos were mounted with 1.5% low melting agarose in PBS. Confocal 
sections  (1.3  µm)  were  taken  with  a  Zeiss  LSM710  confocal  microscope 
covering the entire heart. Images were processed with the software LSM Image 
Browser to obtain projections (Zeiss). Mounted tissue sections were used for 
brightfield microscopy. Cell counting experiments were done with the help of 
ImageJ software. 
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3.23  Statistical analysis 
Data are expressed as mean ± SEM of at least three independent experiments. 
Statistical  significance  of  differences  was  evaluated  by  One-way  ANOVA 
followed  by  Bonferroni's  post-hoc  test  (GraphPad  Prism).  p  <  0.05  was 
considered statistically significant. Results    50 
4.  Results 
4.1  npnt  is  transiently  expressed  during  mammalian  heart 
development 
One  aim  of  our  laboratory  is  the  identification  of  novel  regulators  of  heart 
development.  For  this  purpose  we  performed  a  large  scale  temporal  RNA 
expression analysis  based  on microarray technology.  This analysis revealed 
the expression profile of over 28000 genes from E11 to P10.5 (unpublished 
data). From this study we have identified the gene npnt, encoding the protein 
Nephronectin,  as  transiently  expressed  in  the  rat  heart  at  the  time  of  valve 
initiation, valve formation and trabeculation (E11 to E17) (Figure 4.1A) (105). 
These results were confirmed by RT-PCR for both known variants of rat npnt 
using independent sets of mRNA (Figure 4.1B).  
RT-PCR data using mRNA isolated from mouse hearts showed that also 
both  known  mouse  npnt  variants  are  transiently  expressed  exhibiting  a 
comparable  cardiac  expression  profile  as  the  rat  variants  (Figure  4.1C).  To 
determine whether Npnt is also expressed on protein level in the heart and to 
assess its spatial expression pattern in the rat heart we performed enzymatic 
immunostaining on paraffin tissue sections of E14 rat embryos (Figure 4.1D-G). 
Immunostaining  data  suggest  that  around  this  stage  Npnt  expression  is 
confined to the myocardium, whereas endocardial and epicardial layers did not 
express detectable levels of nephronectin (Figure 4.1E-G).  
The myocardial layer consists of cardiomyocytes and non-myocytes, like 
fibroblasts as well as smooth muscle cells and endothelial cells from vessels 
and microvessels. To assess which cell type expresses nephronectin we have 
isolated  cardiomyocytes  and  non-myocytes  from  postnatal  day  P1  heart 
ventricles  and  isolated RNA from both cell fractions. RT-PCR data revealed 
that  both  the  cardiomyocyte  and  the  non-myocyte  cell  fraction  express  npnt 
(Figure 4.1H).  
Taken together, our data demonstrate that npnt is transiently expressed 
in  cardiomyocytes  and  non-myocytes  of  the  myocardial  layer  during 
mammalian  heart  development  at  the  time  of  cardiac  valve  formation  and 
trabeculation. 
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Figure  4.1:  npnt  is 
transiently  expressed 
during  rat  and  mouse 
heart  development.  (A) 
npnt  expression  levels  in 
rat  heart  tissue  from 
embryonic  day  E11  to 
postnatal day  P10.5  in  12 
hours  intervals  according 
to  a  microarray  analysis 
using Affymetrix GeneChip 
Rat  Expression  Set  230. 
(B)  RT-PCR  analysis  of 
npnt  mRNA  expression 
during  rat  heart 
development.  mRNA  was 
isolated  from  rat  heart 
tissue  collected  at 
sequential  developmental 
stages as indicated. Equal 
amounts  were  loaded  as 
verified by using gapdh as 
a  loading  control.  (C)  RT-
PCR  analysis  of  npnt 
mRNA  expression  during 
mouse heart development. 
mRNA  was  isolated  from  mouse  whole  heart  tissue  collected  at  sequential  developmental 
stages  as  indicated.  Equal  amounts  were  loaded  as  verified  by  using  gapdh  as  a  loading 
control. (D-G) Npnt expression in the rat heart was determined by enzymatic immuonostaining 
on the paraffin sections from E14.5 rat embryos. (D) Brightfield image of the negative control. 
(E-G)  Brighfield  images  showing  Npnt  expression  in  the  myocardium  (black  arrowhead) 
whereas  epicardium  (green  arrow)  and  endocardium  (black  arrow)  are  devoid  of  Npnt 
expression. (H) RT-PCR analysis of npnt mRNA expression in the cardiomyocyte and non-
myocyte  fraction isolated from P3  hearts.  Equal  amounts  were  loaded as  verified  by  using 
gapdh as a loading control. A: atrium; V: ventricle; E: embryonic day; P: postnatal day. Scale 
bars: 50 µm. 
 
4.2  Cloning for in situ probe and full length npnt synthesis 
We have cloned 521 bp of the coding sequence of npnt to synthesize an in situ 
probe against npnt. In addition we have cloned full length npnt to synthesize in Results    52 
vitro capped mRNA  for rescue  experiments. We have  sequenced all cloned 
npnt cDNAs. Interestingly, they were not fully identical to the npnt sequence 
published by NCBI (NM_001145580.1) on 23
rd of November 2010. As per NCBI 
data  npnt  contains  13  exons  and  the  last  exon  contains  a  stop  codon.  Our 
sequencing report indicates that all of our clones lacked exon E3 (51 bp) and 
part of exon E13 including the stop codon. Instead, our data suggest that npnt 
contains one extra exon (E14) containing part of the coding sequence, a stop 
codon and part of the 3’ UTR (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Comparison of the sequence results (red) to the published NCBI sequence (black). 
ATG: start codon. TAA or TGA: stop codons. Results    53 
We assume that the cloned cDNA represents the npnt mRNA. Our full 
length clone contains part of the 5’ UTR, full coding sequence and part of the 
3’ UTR.  
 
4.3  npnt is transiently expressed in the heart during zebrafish 
development 
To determine the expression pattern of npnt in zebrafish we performed whole-
mount  in  situ  hybridization  analyses  using  sense  and  antisense  riboprobes 
against npnt (Figure 4.3). At 24 hpf npnt is markedly expressed at the tail bud, 
head,  in  the  posterior  part  of  the  gut  and  in  the  pharyngeal  endoderm 
(Figures 4.3B,C).  
 
Figure  4.3:  npnt  is 
transiently  expressed 
during  zebrafish  heart 
development.  (A-O) 
Zebrafish  npnt  expression 
was  determined  by  whole-
mount  in  situ  hybridization 
using  antisense  probe 
(B,C,E,F,H,I,K,L,N,O)  and 
sense  probe  (A,D,G,J,M) 
as  a  negative  control.  (B) 
Lateral  view  of  a  24  hpf 
embryo  showing  npnt 
expression in tailbud (white 
arrowhead),  head  (black 
arrow) and posterior part of 
the gut (white arrow). (C) Dorsal view of the anterior part of the trunk is demonstrating npnt 
expression in pharyngeal endoderm (black arrows). (E,F) Lateral and dorsal view at 34 hpf 
showing  npnt  expression  in  the  pronephric  region  (arrows)  and  head  (E,  arrowhead).  (H,I) 
Ventrolateral view (H) and parasaggital section (I) at 44 hpf demonstrating npnt expression in 
heart  (arrow)  and  jaw  (arrowhead).  (K)  Dorsal  view  showing  npnt  expression  at  53  hpf  in 
pharynx,  esophagus  (arrow)  and  pharyngeal  endoderm  (arrowheads).  (L)  Cross-section 
through the trunk confirming npnt expression in the endodermal cells of the anterior gut (arrow). 
(N)  Lateral  view  of a 75  hpf  embryo  demonstrating  npnt  expression in  head  (white  arrow), 
pectoral fin (black arrowhead), pharyngeal arches (black arrow) and cloaca (red arrowhead) (O) 
Ventral view of a embryo is demonstrating npnt is expressed in the bulbus (black arrows) at 75 
hpf. A: atrium; V: ventricle; Scale bars: 100 µm. Results    54 
At 34 hpf highest  expression  of npnt  was observed in the  pronephric 
region, with persistent expression in the head (Figures 4.3E,F). npnt expression 
in  the  heart  was  first  detected  at  44  hpf  (Figure  4.3H)  when  it  was  also 
expressed  in  pharyngeal  pouch  and  mandibular  cartilage  (Figure  4.3H). 
Parasaggital sections of the 44 hpf embryonic heart demonstrated that npnt is 
expressed throughout the heart (Figure 4.3I). Cardiac npnt expression was still 
observed at 48 hpf but was undetectable at 53 hpf when npnt expression was 
most  prominent  in  the  pharynx,  esophagus  and  the  pharyngeal  endoderm 
(Figures 4.3K,L). At 75 hpf npnt is markedly expressed at the head, pectoral fin 
cloaca,  cardiac  bulbus,  and  pharyngeal  arches  but  was  undetectable  in  the 
cardiac chambers (Figures 4.3N,O). Taken together, our data demonstrate that 
npnt is transiently expressed in the heart during zebrafish development. 
 
4.4  Npnt knockdown utilizing different morpholinos 
To assess the role of Npnt in zebrafish heart development morpholinos were 
used  to  knock  down  Npnt  protein  levels.  Three  different  morpholinos  were 
designed:  one  translation  inhibitory  morpholino  (MO1),  binding  at  the  start 
codon and part of 5’ UTR, and two splicing inhibitory morpholinos (MO2 and 
MO3), targeting the splice donor site of exon E4 (MO2) or the splice donor site 
of exon E1 (MO3) (Figures 4.4A,B). Our data indicate that both MO2 injection 
(1.4  to  2.0  pmol)  and  MO3  injection  (1.4  to  2.4  pmol)  were  effective  in 
disrupting correct splicing of npnt pre-mRNA resulting in a marked decrease of 
mature npnt mRNA (Figures 4.4C,D). RT-PCR analyses with the primer pair 
F2/R  demonstrated  that  MO2  injection  resulted  in  exon  E4  deletion  (Figure 
4.4C). cDNA sequencing revealed that MO2 injection resulted not in a frame 
shift but in the deletion of 120 bp encoding one EGF domain. To determine 
whether  a  shortened  Npnt  protein  is  produced  we  perfomed  Western  blot 
analyses utilizing a polyclonal anti-Npnt antibody. Injection of MO1 (3.5 pmol), 
MO2 (1.4 pmol) and MO3 (2.4 pmol) resulted in a marked decrease of Npnt 
protein  level  and  no  truncated  Npnt  protein  was  detected  (Figure  4.4E). 
Therefore,  all  subsequent  studies  were  performed  using  these  amounts  of 
morpholinos. Taken together, our results demonstrate that injection of MO2 and 
MO3 efficiently knocked down the expression of npnt on mature mRNA and for 
MO1, MO2 and MO3 also on protein level. Results    55 
Figure  4.4:  Morpholino-
mediated  Npnt  knock-
down. (A,B) Scheme of the 
effect  of  the  npnt  splice 
inhibitory  morpholino  MO2 
and  MO3.  Exons  are 
represented  by  boxes  with 
numbers  and  introns  by 
lines.  Dotted  lines  indicate 
the region targeted by MO1 
(translation  inhibitory 
morpholino)  or  MO2  and 
MO3.  Arrows  indicate  RT-
PCR primer positions in the 
npnt  gene.  (C)  RT-PCR 
analysis  of  mRNAs  from 
control  and  MO2-injected 
embryos  at  52  hpf  using  the  npnt  primers  as  indicated  in  (A)  and  gapdh  primers  (loading 
control). MO2 inhibited npnt pre-mRNA splicing resulting in exon E4 deletion (n=3). (D) RT-
PCR analysis  of mRNAs  from  control  and  MO3-injected embryos  at  52 hpf using the  npnt 
primers as indicated in (B) and gapdh primers (loading control). MO3 inhibited npnt pre-mRNA 
splicing resulting in downregulation of mature npnt mRNA production (n=3). (E) Western blot 
analysis of protein extracts from control and either MO1-, MO2- or MO3-injected embryos at 52 
hpf (n=3). All three morpholinos efficiently knocked down Npnt protein level. 
 
4.5  Npnt knockdown disrupts heart development and is lethal 
To determine the effect of Npnt knockdown on zebrafish heart development we 
injected  morpholinos  in  embryos  of  transgenic  zebrafish  Tg(myl7:EGFP-
HsHRAS)
s883 (n > 200, 4 independent experiments). In these zebrafish GFP is 
localized  at  the  cardiomyocyte  plasma  membrane  facilitating  the  analysis  of 
heart morphology in living zebrafish. MO1, MO2 or MO3 injection did not show 
any  obvious  effect  on  zebrafish  development  until  40  hpf.  However,  Npnt 
knockdown resulted in 89% ± 7.9% lethality at 7 dpf (Figure 4.5A). The first 
obvious  phenotype  observed  was  pericardial  edema  at  75  hpf  indicating  a 
cardiac defect (Figure 4.5B). A closer analysis of the morphant hearts revealed 
that  valve  leaflet  formation  at  110  hpf  is  perturbed  in  86%  ±  3.9%  of  the 
morphants, resulting in > 30% of those in the lack of valve leaflets (Figures 
4.5C,D). The morphants are also characterized by swelling of the cardiac jelly Results    56 
separating  the  endocardium  and  myocardium  throughout  the  heart  (Figure 
4.5D).  Taken  together,  our  data  indicate  that  Npnt  is  essential  for  cardiac 
development in zebrafish. 
 
 
Figure  4.5:  Morpholino-mediated  Npnt  knockdown  disrupts heart  development  and  is 
lethal. (A) Npnt knockdown resulted in 89% ± 7.9% lethality at 7 dpf. (B) Lateral view of control, 
MO1-,  MO2-  or  MO3-injected  embryos  at  75  hpf.  MO1-,  MO2-  or  MO3-mediated  Npnt 
knockdown resulted in pericardial edema (arrowheads). Scale bars: 500 µm. (C) Quantitative 
analysis is indicating that valve formation is perturbed in 86% ± 3.9% morphant hearts at 110 
hpf. (D) H & E stained saggital sections of hearts from control and MO2-injected embryos at 
110  hpf  are  showing  morphant  hearts  that  failed  to  form  proper  valve  leaflets  at  the  AV 
boundary. White circle highlights properly formed AV valve leaflets in control embryos. Black 
arrowheads indicate AV boundary and green double arrows indicate expanded cardiac jelly. A: 
atrium; V: ventricle; PC: pericardium. Scale bars: 50 µm. 
 
4.6  Npnt knockdown causes an extended AV canal 
To determine the earliest effect of Npnt knockdown on the morphology of the 
heart either MO1, MO2 or MO3 was injected in embryos of transgenic zebrafish 
Tg(myl7:EGFP-HsHRAS)
s883 (n > 200, 4 independent experiments). Compared 
to control hearts from non-injected or phenol red-injected embryos, hearts from 
morpholino  (either  MO1  or  MO2  or  MO3)-injected  embryos  exhibited  an 
extended tube like structure at the AV boundary at 52 hpf (Figure 4.6A). 
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Figure 4.6: Depletion of 
Npnt  by  three  different 
morpholinos causes an 
extended  AV  canal  (A) 
Morpholino-injected 
embryos  from  transgenic 
zebrafish Tg(myl7:EGFP-
HsHRAS)
s883  showed  an 
expansion  of  the  AV 
canal at 52 hpf compared 
to  control  embryos.  (B) 
Nomarski  (DIC)  images 
of hearts from control and 
morpholino-injected 
embryos  at  52  hpf 
representing  AV  canal 
expansion  defects. 
Depending on severity of 
heart defects phenotypes 
were classified into type I 
(mild extension of the AV 
canal),  type  II  (clear 
extension  of  the  AV 
canal)  and  type  III 
(straight  heart).  Brackets 
indicate  the  AV 
boundary.  (C) 
Quantitative  analysis  of  embryos  regarding  AV  canal  expansion  in  total  (n  >  150  from  3 
independent experiments, mean ± SEM). (D) Quantitative analysis regarding type I, type II and 
type III AV canal expansion. Note that type II was the most common phenotype (over 50%) in 
both MO1- and MO2-injected embryos. A: atrium; V: ventricle. Scale bars: 50 µm. 
 
Based on the severity of the cardiac defect at 52 hpf morphants were 
categorized into three classes: type I (mild extension of the AV canal), type II 
(clear extension of the AV canal), type III (straight heart) (Figure 4.6B). MO1 
injection caused heart defects in 71% ± 4.0% (type I: 29% ± 2.6%, type II: 54% 
± 5.3%, type III: 17% ± 8.3%) and MO2 injection in 86% ± 4.4% (type I: 21% ± 
3.2%, type II: 56% ± 4.0%, type III: 23% ± 3.9%) of injected embryos (Figures 
4.6C,D).  All  three  morpholinos  resulted  in  Npnt  knockdown  and  in  similar 
phenotypes  suggesting  that  the  observed  phenotypes  are  a  functional Results    58 
consequence  of  Npnt  depletion  and  earliest  morphological  phenotype  is  an 
extension of the AV canal. 
 
4.7  Microinjection of npnt mRNA rescues AV canal extension 
To prove that the observed cardiac phenotypes are specific to the depletion of 
Npnt, rescue experiments were performed by co-injecting in vitro transcribed 
capped npnt mRNA and MO2. Efficiency of in vitro transcription and the correct 
size of the in vitro synthesized capped npnt mRNA (2100 kb) were confirmed 
by denaturing agarose gel electrophoresis (Figure 4.7A). Note that, MO2 is a 
splice  inhibitory  morpholino  that  does  not  affect  translation  of  injected  npnt 
mRNA.  
The  sequence  of  all  cloned  npnt  cDNAs  were  identical  but  in  part 
different from the published npnt sequence by NCBI on 23
rd of November 2010 
(see 4.2 and Figure 4.2). Assuming that the cloned cDNA represents the npnt 
mRNA  at  52  hpf,  we  used  linearized  pCS2+-Fnpnt  plasmid  as  template  to 
generate  capped  npnt  mRNA  for  rescue  experiments.  Injection  of  30  pg  of 
capped npnt mRNA had no effect on cardiac development and did not rescue 
the MO2-induced AV canal extension defects. In contrast, injection of 50 pg of 
capped npnt mRNA rescued the AV canal extension defect in a subset of MO2-
injected  embryos  (Figure  4.7B)  and  had  only  a  minor  effect  on  cardiac 
development  when  injected  alone  (88%  ±  1.46%  normal  hearts  at  52  hpf, 
Figure  4.7C).  Importantly,  40%  ±  2.33%  of  embryos  had  normal  AV  canal 
length after co-injection of mRNA and MO2 compared to 11% ± 2.0% after only 
MO2-injection (Figure 4.7C). In addition, injection of 50 pg capped npnt mRNA 
markedly reduced the severity of the cardiac extension defect in the remaining 
embryos  with  defective  hearts  resulting  in  an  increased  amount  of  type  I 
defects (23.6% ± 1.21% to 48.7% ± 2.38%) and a decrease in type II defects 
(60% ± 1.09% to 26.5% ± 2.6%) (Figure 4.7D). The slight increase in the type 
III phenotype (16.4% ± 2.38% to 24.8% ± 2.41%) might be due to the npnt 
overexpression phenotype. Rescued embryos did not form cardiac edema at 
75  hpf  (Figure  4.7E).  Injection  of  80  pg  capped  npnt  mRNA  caused  severe 
defects in zebrafish development including cyclopia and heart defects (Figure 
4.7F). In summary, our data show that the MO-mediated phenotypes are due to Results    59 
Npnt  protein  depletion  and  demonstrate  that  Npnt  is  required  for  heart 
development in zebrafish. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Extended AV canal of Npnt morphant hearts could be rescued by in vitro 
synthesiszed  capped  npnt  mRNA  injection.  (A)  Denatured  agarose  gel  picture 
demonstrating the size of the in vitro synthesized capped npnt mRNA after electrophoresis. (B) 
Representative images of hearts from control, MO2- and MO2+npnt mRNA-injected embryos 
from transgenic zebrafish Tg(myl7:EGFP-HsHRAS)
s883 at 52 hpf (scale bars: 50 µm). Brakets 
indicate the AV boundary. (C) Quantitative analysis of the rescue experiment scoring for normal 
hearts (n > 160 from three independent experiments, mean ± SEM). (D) Quantitative analysis 
of the rescue experiment scoring type I, type II and type III AV canal defects. (E) Lateral view of 
control, npnt mRNA, MO2- or MO2 + npnt mRNA-injected embryos at 75 hpf (scale bars: 500 
µm). Note that injection of npnt mRNA rescued the Npnt-depleted AV canal extension defect 
and pericardial edema (arrowhead). (F) Lateral view of control, or 80 pg capped npnt mRNA-
injected  embryos  at  75  hpf.  Note  that,  >50%  embryos  carry  pericardial  edema  (black 
arrowhead) and >25% embryos carry cyclopia (black arrow) as an overexpression phenotype 
(scale bars: 500 µm). A: atrium; V: ventricle.  Results    60 
4.8  Npnt  depletion  does  not  affect  the  total  number  of 
cardiomyocytes 
To better characterize the functional consequence of Npnt depletion for heart 
development  the  transgenic  zebrafish  lines  Tg(myl7:EGFP-HsHRAS)
s883 
expressing  GFP  at  the  cardiomyocyte  plasma  membrane  and  Tg(-
5.1myl7:nDsRed2)f2  expressing  RFP  in  cardiomyocyte  nuclei  were  used. 
Projections  of  cardiac  optical  sections  from  Tg(myl7:EGFP-HsHRAS)
s883 
control and Npnt morphant embryos at 52 hpf showed no obvious differences in 
the morphology of chamber cardiomyocytes (Figures 4.8A,B). In contrast, the 
morphology  of  the  AV  boundary  was  affected  by  Npnt  knockdown.  Npnt 
morphants  exhibited  an  extended  tube  like  structure  at  the  AV  boundary 
(Figures 4.8B,D) compared to the control hearts (Figures 4.8A,C).  
 
 
 
 
 
 
 
 
 
 
 
Figure  4.8:  The  AV  canal  of  Npnt  morphants  is  expanded,  without  affecting 
cardiomyocyte number. (A-D) Projections of confocal images of hearts from control (A,C) and 
MO2-injected (B,D) embryos from transgenic zebrafish Tg(myl7:EGFP-HsHRAS)
s883 (A,B) and 
Tg(-5.1myl7:nDsRed2)f2 (C,D) at 52 hpf suggesting an extension of the AV canal (brackets) in 
Npnt morphants. (E) Quantitative analysis scoring total number of cardiomyocytes in hearts 
from control and Npnt depleted embryos. A: atrium; V: ventricle. Scale bars: 50 µm. (n =5, 
mean ± SEM).  
 
An  extension  of  the  AV  canal  could  either  be  due  to  an  increase  in 
proliferation  of  AV  cells  or  a  patterning  defect,  meaning  that  more  cells 
differentiate  into  AV  cells  at  the  expense  of  chamber  cells.  Cell  count Results    61 
experiments  using Tg(-5.1myl7:nDsRed2)f2 embryos  at  52  hpf revealed that 
the  overall  number  of  cardiomyocytes  (chambers  +  AV  boundary)  was  not 
significantly different between control and morphant hearts (205 ± 7.5 vs. 192 ± 
6.8, n = 5) (Figure 4.8E). These data indicate that the extension of the AV canal 
was due to an increase in cells differentiating into AV canal cells at the expense 
of chamber cells, without affecting cardiomyocyte proliferation. 
To evaluate which chamber cells contribute to the additional AV canal 
cells  we  performed  immunostaining  against  atrial  myosin  heavy  chain  on 
embryos  from  double  transgenic  animals  (Tg(-5.1myl7:nDsRed2)f2  x 
Tg(myl7:EGFP-HsHRAS)
s883) (Figure 4.9).  
 
Figure  4.9.  Additional  AV  canal 
cells  might be at  the  expense of 
ventricular  cells.  (A-F)  Projections 
of  confocal  images  of  hearts  from 
whole-mount  atrial  myosin  heavy 
chain-  (white)  and  DsRed-stained 
(red) control (A-C) and MO2-injected 
(D-F)  embryos  from  double 
transgenic  animals  (Tg(-
5.1myl7:nDsRed2)f2  x 
Tg(myl7:EGFP-HsHRAS)
s883).  (G) 
Quantitative  analysis  of  the  overall 
number  of  cardiomyocytes 
(chambers + AV boundary) and the 
number of atrial cardiomyocytes. A: 
atrium;  V:  ventricle.  Scale  bars:  50 
µm. (n=5, mean ± SEM). 
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Atrial  myosin  heavy  chain  staining  markes  only  cardiomyocytes  from 
atrial origin, thus it helps to identify the origin of the additional cardiomyocytes 
in  the  extended  AV  canal.  As  in  the  previous  experiment  (Figure  4.8E)  the 
overall  number  of  cardiomyocytes  (chambers  +  AV  boundary)  was  not 
significantly  different  between  control  and  morphant  hearts  (Figure  4.9G). 
Counting  of  cardiomyocytes  in  hearts  stained  for  atrial  myosin  heavy  chain 
revealed  that  also  the  number  of  atrial  cardiomyocytes  was  not  significantly 
different  between  control  and  morphants  hearts  (Figure  4.9).  These  data 
suggest  that  the  extension  of  the  AV  canal  is  due  to  an  increase  in  cells 
differentiating into AV canal cells at the expense of ventricular cells in Npnt 
morphants. 
 
4.9  Npnt  depletion  causes  an  expansion  of  myocardial  AV 
canal gene expression 
To determine how Npnt knockdown affects cardiac AV canal differentiation, we 
assessed  the  expression  of  early  differentiation  markers  of  the  AV  canal 
myocardium like cspg2 (zebrafish versican homolog) and bone morphogenetic 
protein  4  (bmp4).  During  early  cardiac  development  bmp4  and  cspg2  are 
expressed throughout  the  heart in  the  myocardium and  then  later at 37  hpf 
cspg2  expression  becomes  restricted  to  the  AV  canal  region  and  bmp4 
expression restricted to  non-chamber  myocardium (OFT, AV canal  and IFT) 
(37). The expression of another ECM gene, fibulin1 (106), is restricted to the 
AV  myocardium  at  2  dpf.  To  assess  the  effect  of  Npnt  knockdown  on  the 
expression of these AV canal specific myocardial genes at 52 hpf whole-mount 
in  situ  hybridization  analyses  were  performed.  Compared  to  control  hearts 
(Figures  4.10A,C,E)  expression  of  all  these  genes  was  expanded  in  Npnt 
morphant hearts at the AV boundary at 52 hpf (Figures 4.10B,D,F). In addition, 
ectopic expression of cspg2 was detected at the IFT (Figure 4.10D). 
  The expression of the ventricular cardiomyocyte specific gene vmhc and 
the atrial cardiomyocyte specific gene amhc is first evident at the 19 somite 
stage  (16  hpf)  (65).  To  assess  the  affect  of  Npnt  knockdown  on  chamber 
specific expression of the marker genes vmhc and amhc in situ hybridization 
was  performed.  Expression  of  the  chamber  specific  marker  genes  was 
unaffected  in  Npnt  morphant hearts (Figures  4.10G,H,I,J). Our  data indicate Results    63 
that the extended tube like structure represents an extended AV canal on a 
molecular level. 
Figure  4.10:  Npnt 
morphant hearts have an 
extended AV canal at the 
molecular  level  in  the 
myocardium.  (A-F) 
Sections of 52 hpf control 
and  MO2-injected 
embryos  after  whole-
mount in situ hybridization 
with probes against bmp4 
(A,B) and the ECM genes 
cspg2  (C,D)  and  fibulin1 
(E,F).  The  expression 
pattern  of  these  genes 
was  expanded  in  the 
myocardium  of  Npnt 
morphants  (brackets).  (G-
J)  Sections  of  52  hpf 
control  (G,I)  and  MO2-
injected  (H,J)  embryos 
after  whole-mount  in  situ 
hybridization  with  probes 
against  the  chamber-
specific  marker  genes 
amhc  and  vmhc.  Npnt  knockdown  does  not  affect  the  expression  pattern  of  the  chamber-
specific genes. Arrowheads indicate AV canal. A: atrium; V: ventricle. Scale bars: 50 µm. 
  
4.10  Npnt  morphant  hearts  have  an  extended  AV  canal 
endocardium  
Our data regarding myocardial cells suggest that the extension of the AV canal 
is due to a defect in Npnt morphants to restrict AV canal differentiation. Initially 
notch1b  is  expressed  throughout  the  anteroposterior  extent  of  the  cardiac 
endocardium  but  at  45  hpf  expression  is  restricted  to  the  AV  valve-forming 
region  (107).  To  determine  how  Npnt  knockdown  affects  endocardial 
differentiation  at  the  AV  canal,  we  assessed  the  expression  of  early 
differentiation  markers  of  the  valve  forming  AV  canal  endocardium.  In 
accordance with an expanded AV canal endocardial expression of notch1b was Results    64 
expanded in Npnt morphant hearts at the AV boundary at 52 hpf compared to 
control  hearts  (Figures  4.11A,B).  Another  AV  canal  marker  is  Alcam,  a  cell 
surface  adhesion  molecule  (108),  which  is  localized  to  the  lateral  side  of 
myocardial cells and differentiated AV canal endocardial cells (81). During early 
cardiac development endocardial cells are squamous and Alcam-negative, but 
at 36 hpf a single tier of cells at the border between the atrium and the ventricle 
differentiates into a cuboidal shaped Alcam-positive cell (81). This change in 
shape and the initiation of Alcam expression are the earliest manifestations of 
endocardial differentiation in the AV canal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: The AV canal endocardium of Npnt morphants is expanded. (A,B) Sections of 
52 hpf control and MO2-injected embryos after whole-mount in situ hybridization with a probe 
against notch1b. Expression was expanded in Npnt morphants (brackets). Confocal sections of 
whole-mount  Alcam-stained  (red:  myocardium  and  differentiated  endocardial  cells)  control 
(C,D) and MO2-injected (F,G) embryos from transgenic zebrafish Tg(kdrl:EGFP)
s843 at 52 hpf. 
Morpholino-mediated knockdown of Npnt caused an increase of differentiated endocardial cells 
(cuboidal-shaped, Alcam- and EGFP-positive) from < 6 tiers to at least 8 - 12 tiers of cells at 
the AV boundary. Arrowheads indicate AV boundary. (E,H) Schematic drawings of D and G 
respectively  (red  line:  myocardium;  green:  endocardial  cells;  black  dots:  Alcam-positive 
endocardial cells). (I) Quantitative analysis: The AV canal endocardium in Npnt morphants is 
extended by 86% ± 13.1% (mean ± SEM) in comparison to control hearts. Arrowheads: AV 
boundary; A: atrium; V: ventricle. Scale bars: 50 µm. 
To examine endocardial cell differentiation in more detail embryos from 
the  transgenic  zebrafish  line  Tg(kdrl:EGFP)
s843  expressing  GFP  in  all Results    65 
endothelial cells were used and counter stained with an anti-Alcam antibody. At 
the AV boundary 5 to 6 tiers of endocardial cells expressed Alcam in control 
hearts at 52 hpf (Figures 4.11C,D,E). In contrast, in the Npnt morphants 8 to 12 
tiers of cells at the AV canal region were Alcam-positive (Figures 4.11F,G,H). 
Taken together, these data indicate that Npnt knockdown caused a patterning 
defect resulting  in an increased number  of differentiated AV myocardial and 
endocardial cells and thus an extended AV canal.  
 
4.11  Npnt  knockdown  causes  abnormal  expansion  of  the 
cardiac jelly 
Myocardium and endocardium are separated by ECM that is termed cardiac 
jelly.  One  characteristic  of  the  AV  cells  is  an  increased  expression  of  ECM 
components at the onset of looping (37, 49), which facilitates endocardial cell 
migration. Around 30 hpf, visibly distinct ventricular and atrial chambers form 
and by 36 hpf the heart undergoes looping morphogenesis (81).  
Figure 4.12: Npnt knockdown causes 
cardiac jelly expansion and expanded 
expression of has2, tbx2b and bmp4. 
(A,B)  Confocal  sections  from  whole-
mount  F-actin-stained  (red)  control  (A) 
and  MO2-injected  (B)  embryos  heart 
from  transgenic  zebrafish 
Tg(kdrl:EGFP)
s843 at 52 hpf. The space 
between  endocardium  and  myocardium 
(cardiac  jelly)  was  increased in  the  AV 
boundary  (arrowheads)  as  well  as 
throughout the chambers (red asterisks) 
in Npnt morphants. (C-H) Sections of 52 
hpf  control  and  MO2-injected  embryos 
after  whole-mount  in  situ  hybridization 
showing has2, tbx2b and bmp4 expression at the AV boundary (brackets). Note that expression 
of all analyzed genes is expanded in Npnt morphants. A: atrium; V: ventricle. Scale bar: 50 µm. 
To  determine  whether  the  extended  AV  canal  is  producing  normal 
amounts  of  cardiac  jelly,  embryos  from  the  transgenic  zebrafish  line 
Tg(kdrl:EGFP)
s843 were used. Embryos were counter stained with rhodamine 
phalloidin (detects F-actin) to visualize the myocardium. Results    66 
Analysis of confocal sections of hearts from control and Npnt morphant 
hearts at 52 hpf showed that the space between endocardium and myocardium 
is markedly increased in the morphants at the AV region as well as chambers 
(Figures 4.12A,B). This suggests that  Npnt  knockdown  caused an abnormal 
expansion  of  the  cardiac  jelly.  A  major  constituent  of  the  cardiac  jelly  is 
glycosaminoglycan  hyaluronan  (HA)  which  is  synthesized  by  the  enzyme 
hyaluronan synthase 2 (has2) (53). It has multiple functions during AV canal 
morphogenesis:  First,  HA  is  required  to  form  expanded  cardiac  jelly  that 
facilitates  endocardial  cell  migration.  Second,  it  promotes  Ras-dependent 
transformation  into  pre-valvular  mesenchyme  and  provides  a  migratory 
substrate for these invasive cells  (53).  has2 is  a downstream target of  tbx2 
(109). Both of these genes are known to be regulated by BMP signaling (53, 
109, 110). In wild type zebrafish the expression of has2 is restricted to the AV 
boundary endocardium (49), whereas bmp4 and tbx2 expression is restricted to 
the AV boundary myocardium at 2 dpf (37, 49, 111) (Figures 4.12C,E,G). bmp4 
is in addition expressed at the OFT and IFT (Figure 4.12G) (37). In contrast, 
expression of has2, tbx2b and bmp4 are expanded in Npnt morphants at the 
AV boundary (Figures 4.12D,F,H). Taken together, these results suggest that 
Npnt is an inhibitory upstream regulator of bmp4, tbx2b, and has2 expression 
controlling cardiac jelly formation. 
 
4.12  Npnt knockdown causes abnormal trabeculation  
It has been reported that ventricular trabeculation is initiated at around 72 hpf 
by  protrusion  of  cardiomyocytes  out  of  the  monolayered  ventricular 
myocardium, generating small clusters of cells (74, 112). To evaluate whether 
trabeculation is affected in Npnt morphant hearts we examined confocal optical 
sections  of  the  hearts  from  80  hpf  Tg(myl7:EGFP-HsHRAS)
s883  control  and 
MO2-injected embryos. Consistent with published data control embryos exhibit 
around 80 hpf highly trabeculated ventricles (Figures 4.13A,B). In contrast, the 
Npnt morphant hearts were devoid of trabeculation (Figures 4.13C,D). Saggital 
confocal  sections  revealed  that  myocardial  cells  are  disorganized  in  Npnt 
morphants  at  80  hpf  (Figures  4.13C,D).  H&E  stained  cardiac  sections  of 
110 hpf embryos showed finger like projections (trabeculae) extended into the 
ventricular lumen from monolayered compact myocardium. In contrast, in Npnt Results    67 
morphant hearts the monolayered ventricular myocardium remains devoid of 
trabeculae.  In  addition  endocardium  and  myocardium  in  control  hearts  are 
separated  by  a  thin  layer  of  cardiac  jelly  whereas  in  Npnt  morphant  hearts 
extensive  cardiac  jelly  is  present  (Figures  4.13E,F).  Thus,  Npnt  knockdown 
causes not only an extension of the AV canal but also perturbed trabeculation. 
 
Figure 4.13: Npnt depletion perturbed 
ventricular  trabeculation.  (A,B) 
Confocal  images  of  hearts  from  control 
(A) and MO2-injected (B) embryos from 
transgenic  zebrafish  Tg(myl7:EGFP-
HsHRAS)
s883  at  80  hpf  suggesting 
initiation  of  trabeculation  of  the 
ventricular myocardial layer is perturbed 
in  Npnt  morphants.  Red  arrows: 
trabculae. (C,D)  H &  E stained saggital 
sections  of  hearts  from  control  (C)  and 
MO2-injected  (D)  embryos  at  110  hpf. 
Control  embryos  develop  in  contrast  to 
morphant embryos proper trabeculae on 
the  ventricular  myocardial  wall  (red 
arrows). Black arrowhead: AV boundary; 
green arrows: expanded cardiac jelly; A: 
atrium; V: ventricle. Scale bars: 50 µm. 
 
 
 
4.13  Has2 knockdown reduces the number of AV endocardial 
cells 
The transformation of endothelium to mesenchyme is a prerequisite for valve 
leaflet  formation  (113).  Both  the  mechanism  behind  the  stimulation  of  the 
myocardium to release activation signals and the acquisition of the signal by 
the  endocardium  are  poorly  understood  (114).  One  important  molecule  to 
enable  EMT  is  Has2.  Studies  using  has2
–/–  embryonic  heart  explants  have 
shown that cardiac endothelial cells failed to transform into mesenchyme, an 
essential developmental event for valvogenesis (53). To determine whether the 
observed expanded expression of has2 caused the increased number of AV 
endocardial cells we performed Has2 knockdown experiments (Figure 4.14). Results    68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Morpholino-mediated has2 knockdown rescues the endocardial phenotype 
in Npnt morphants. (A) Confocal sections of whole-mount Alcam-stained (red: myocardium 
and differentiated endocardial cells) MO2-, MO2/has2 morpholino-co-, has2-MO- and control 
injected  embryos  from  transgenic  zebrafish  Tg(kdrl:EGFP)
s843  at  52  hpf.  (B)  Schematic 
drawings  of  A  (red  line:  myocardium;  green:  endocardial  cells;  black  dots:  Alcam-positive 
endocardial  cells).  Morpholino-mediated  knockdown  of  Npnt  caused  an  increase  of 
differentiated AV endocardial cells (cuboidal-shaped, Alcam- and EGFP-positive) from ≤ 6 tiers 
of cells in the wild type to at least 8 - 12 tiers of cells at the AV boundary. Knockdown of has2 in 
Npnt morphants reduced the number to 1 - 2 tiers of Alcam-positive endocardial cells at the AV 
boundary. Arrowheads indicate AV boundary. (C) Quantitative analysis. has2 knockdown in 
Npnt morphants rescued the AV canal endocardium extension (mean ± SEM). (D) Brightfield 
images of 52 hpf MO2-, MO2/has2 morpholino-co- and has2 morpholino-injected embryos after 
whole-mount  in  situ  hybridization  showing  notch1b  expression  (brackets).  Note  that  has2 
knockdown  reduced  the  expanded  expression  of  notch1b  in  Npnt  morphants  (brackets).  A: 
atrium; V: ventricle. Scale bars: 50 µm. 
Single cell stage embryos were injected with translation blocking has2 
(gift from J. Bakkers) and/or npnt morpholinos and were subsequently analysed 
for the expression of AV endocardial specific genes like Alcam and notch1b at Results    69 
52 hpf. has2 knockdown reduced the increased number of Alcam-positive AV 
endocardial cells from ≥ 8 tiers of cells (183% ± 32.2% compared to control) in 
the Npnt morphants to ≤ 3 tiers of cells (31% ± 11.9% compared to control) at 
the AV canal region (Figures 4.14A,B,C). has2 knockdown in control embryos 
resulted also in reduced numbers of Alcam-positive AV endocardial cells from ≥ 
5 tiers of cells to ≤ 2 tiers of cells at the AV canal region (Figures 4.14A,B). 
Moreover, has2 knockdown in Npnt morphant or control embryos resulted in 
the  reduction  or  abolishment  of  notch1b  expression  (Figures  4.14C).  Taken 
together our data suggest that the increased number of AV endocardial cells in 
Npnt morphants is at least in part due to the expanded expression of has2. 
 
4.14  bmp4  and  cspg2  misexpression  is  not  dependent  on 
expanded has2 misexpression 
To better understand the function of Npnt we were interested to elucidate how 
other regulators of valve development are linked to the downstream signaling 
cascade of Npnt. Whole-mount in situ hybridization analyses have shown that 
AV canal myocardium specific expression of bmp4 and cspg2 were expanded 
in Npnt morphant hearts at the AV boundary at 52 hpf compared to control 
hearts (Figures 4.15A-D). To determine whether the expanded expression of 
has2  caused  the  myocardial  phenotype  or  not,  we  determined  by  in  situ 
hybridization analysis the expression of cspg2 and bmp4 after has2 knockdown 
in control and Npnt morphant embryos and uninjected control embryos. Our 
data revealed that the expression of bmp4 in Npnt morphant hearts remained 
unchanged after has2 knockdown (Figures 4.15C,E) and has2 morphant hearts 
showed similar bmp4 expression as uninjected control embryo hearts (Figures 
4.15A,G).  has2  knockdown  in  Npnt  morphants  could  also  not  rescue  the 
expanded expression of cspg2 (Figures 4.15D,F). In addition, has2 knockdown 
in control embryos resulted in expanded expression of cspg2 in comparison to 
uninjected controls (Figures 4.15B,H). These data indicate that has2 is not an 
upstream regulator of cspg2 and bmp4.  
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Figure  4.15:  Morpholino-mediated  has2  knockdown  failed  to  rescue  the  myocardial 
phenotype.  (A-H)  Brightfield  images  of  52  hpf  control,  MO2-injected  and  MO2/has2 
morpholino-co-injected  and  has2  morpholino  injected  embryos  after  whole-mount  in  situ 
hybridization  showing  bmp4  (A,C,E,G)  and  cspg2  expression  (brackets).  Note  that  has2 
knockdown failed to rescue the expanded expression of cspg2 and bmp4 in Npnt morphants 
(brackets and arrows). has2 knockdown in wild type embryos cause up-regulation of cspg2 
(B,H). A: atrium; V: ventricle. Scale bars: 50 µm. 
 
4.15  Diminished  BMP  signaling  reduces  AV  canal expansion 
via inhibition of ectopic expression of has2 and cspg2 
BMP4 is a member of the TGFβ superfamily of cytokines, which is important for 
numerous  developmental  processes  (115,  116).  BMP4  acts  via  activating 
heterodimeric complexes of type I and type II serine/threonine kinase receptors 
(116).  Previous  in  vitro  explant  studies  and  in  vivo  studies  suggested  that 
BMP4 is a key regulator for the initiation of cushion formation as well as for 
proper AV septation (107, 117). However, there is a debate whether BMP4 is 
an  upstream  regulator  of  has2  expression.  Using  explant  cultures  of  late 
gastrula  anterior  lateral  endoderm  from  chicken  it  has  been  shown  that 
inhibition  of  BMP  signaling  does  not  affect  has2  expression  (118).  An 
established  downstream  target  of  BMP-Smad  pathway  is  tbx2  (109,  119). 
Interestingly, a recent study has shown that ventricular tbx2 misexpression in a 
mouse model exhibited increased has2 expression (109). To determine if BMP 
signaling acts downstream of Npnt we inhibited BMP-Smad signaling in Npnt 
morphants at 25 hpf with dorsomorphin, a pharmacological antagonist of type I 
BMP  receptors  (102,  120),  and  analysed  the  embryos  at  52  hpf  regarding 
phosphorylation of Smad. The amount of phosphorylated Smad (p-Smad) was Results    71 
quantified by Western blot analysis, using protein isolated from 52 hpf control 
and  dorsomorphin  treated  embryos  (Figure  4.16A).  Our  p-Smad  antibody 
detected two bands, one at 65 kD and another at 80 kD (Figure 4.16A). The 
amount  of  p-Smad  was  normalized  to  pan-Actin  expression  (Figure  4.16B). 
Western  blot  analysis  revealed  that  dorsomorphin  exhibits  its  maximum 
inhibitory effect at a concentration of 10 µM (Figure 4.16B). Thus, we used 10 
µM dorsomorphin for all of our experiments. 
 
Figure  4.16:  Chemical 
inhibition  of  BMP  signaling 
by  dorsomorphin  rescued 
the  AV  canal  expansion 
phenotype  in  Npnt 
morphants.  (A)  Western  blot 
analysis  of  protein  extracts 
from  48  hpf  control  embryos 
and  embryos  treated  with 
different  concentration  of 
dorsomorphin  at  25  hpf. 
dorsomorphin  shows  highest 
inhibition  of  Smad 
phosphorylation  at  10µM.  (B) 
Quantitative  analysis  of 
Western  blot  analysis  (n  =  4, 
mean ± SEM). (C) Projections 
of  confocal  images  and 
confocal  sections  of  hearts  of 
MO2-injected  Tg(kdrl: 
EGFP)
s843  embryos  at  52  hpf 
with and without dorsomorphin 
treatment stained for Alcam (red: myocardium and differentiated endocardial cells). Inhibition of 
BMP signaling in Npnt morphants decreased the number of Alcam-positive from from ≥ 8 tiers 
of cells to ≤ 6 tiers of cells at AV canal region (basal level). (D) Quantitative analysis. Inhibition 
of BMPs signaling in the Npnt morphants rescued the AV canal endocardium extension (mean 
± SEM). (E) Brightfield images of 52 hpf untreated and dorsomorphin-treated Npnt morphants 
after  whole-mount  in  situ  hybridization  showing  notch1b,  cspg2  and  has2  expression 
(brackets). Data shows that notch1b and has2 expression is reduced at the AV boundary after 
dorsomorphin  treatment.  Moreover,  ectopic  expression  of  cspg2  at  the  inflow  tract  in  Npnt 
morphants is abolished (arrowheads) and cspg2 expression at the AV boundary is partially 
rescued. A: atrium; V: ventricle. Scale bar: 50 µm.  Results    72 
Dorsomorphin  treatment  reduced  the  number  of  Alcam-positive  AV 
endocardial cells from ≥ 8 tiers of cells (166% ± 32.7% compared to control) in 
the Npnt morphants to ≤ 6 tiers of cells (125.3% ± 10.7% compared to control) 
at the AV canal region (Figures 4.16C,D). BMP recptor I inhibition also rescued 
the expanded expression of notch1b expression (Figures 4.16E).  
To assess whether ectopic expression of has2 and cspg2 is dependent 
on BMP signaling, we performed in situ hybridization analyses for has2 and 
cspg2 expression on 52 hpf Npnt morphants and dorsomorphin-treated Npnt 
morphants. Dorsomorphin partially rescued the expanded expression of these 
genes  at  the  AV  region  in  Npnt  morphants  (Figure  4.16E)  and  interestingly 
abolished ectopic expression of cspg2 in the IFT (arrowheads). Taken together, 
our data suggest that knockdown of Npnt causes ectopic expression of bmp4, 
which is mainly responsible for the phenotype of Npnt morphants and suggest 
that BMP is an upstream regulator of has2 and cspg2 in zebrafish heart. 
 
4.16  Chemical  inhibition  of  BMP  signaling  has  no  obvious 
effect on wild type zebrafish embryos hearts 
To assess whether under physiological conditions has2 is a downstream target 
of BMP or not, we treated wild type embryos at 25 hpf with dorsomorphin and 
performed  in  situ  hybridization  analyses  for  has2,  cspg2  and  notch1b 
expression at 52 hpf. In addition we performed immunostaining against Alcam 
to determine changes in endocardial cell differentiation at the AV canal utilizing 
Tg(kdrl:EGFP)
s843 transgenic embryos. In control embryos (wild type) inhibition 
of BMP signaling did not affect basal expression of AV canal marker genes like 
notch1b, has2 and cspg2 (Figure 4.17A) and had no effect on the number of 
Alcam-positive cells (Figures 4.17B,C). Taken together, our data identify Npnt 
as an upstream regulator of BMP signaling. Moreover, these findings suggest 
that ectopic BMP signaling regulates has2 and cspg2. Results    73 
Figure  4.17:  Dorsomorphin-
mediated  inhibition  of  BMP 
signaling  does  not  interfere 
with  the  basal  level  of  AV 
specific gene expression at 52 
hpf. (A) Brightfield images of 52 
hpf  WT  and  10  µM 
dorsomorphin-treated  embryos 
after  whole-mount  in  situ 
hybridization with probes against 
notch1b,  has2  and  cspg2. 
Expression of these genes at the 
AV  canal  region  remained 
unaffected  in  dorsomorphin-
treated  embryos  (bracktes).  (B) 
Confocal  sections  of  whole-
mount  Alcam-stained  (red)  WT 
and 10 µM dorsomorphin-treated 
embryos  from  transgenic 
zebrafish Tg(kdrl:EGFP)
s843 at 52 
hpf. The number of differentiated 
endocardial  cells  (cuboidal-
shaped, Alcam- and EGFP-positive) remained unchanged (5 - 6 tiers of cells at the AV canal 
region) in dorsomorphin-treated animals. Arrowheads indicate AV boundary. (C) Quantitative 
analysis. Inhibition of BMPs signaling in the WT embryos does not affect the basal no of Alcam-
positive cells at the AV canal region (mean ± SEM). A: atrium; V: ventricle. Scale bar: 50µm. 
 
4.17  Wnt/β-catenin signaling is not the downstream target of 
Npnt  
Several  in  vitro  studies  have  shown  that  in  colorectal  cancer  cells  and 
embryonic  stem-cells  the  genes  bmp4,  cspg2  and  has2  are  transcriptional 
targets of the Wnt/β-catenin pathway (121, 122). It has also been suggested 
that AV endocardial differentiation is mediated through Wnt/β-catenin signaling 
(49). To determine whether Wnt signaling is affected in Npnt morpants, MO2 
was injected into embryos transgenic for Tg(TOP:GFP)
w25, a reporter for Wnt/β-
catenin  signaling.  Activation  of  GFP  expression  was  determined  by  in  situ 
hybridization  on  52  hpf  old  embryos.  However,  GFP  signal  was  neither 
detected  in  the  heart  of  Npnt  morphants  nor  in  control  embryos  at  52  hpf. Results    74 
However, we could detect a signal in the head, eyes, jaw and trunk (Figure 
4.18). These data suggested that Npnt does not signal through Wnt signaling 
pathway around 52 hpf in the zebrafish heart. 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.18:  Npnt  knockdown  does  not  result  in  ectopic  activation  of  Wnt/β-catenin 
signaling at 52 hpf in the heart. (A-F) Activation of Wnt/β-catenin signaling was determined 
by whole-mount in situ hybridization against GFP on control and MO2-injected embryos from 
the reporter line Tg(TOP:GFP)
 w25, where activation of Wnt/β-catenin signaling results in GFP 
expression. Dorsal, lateral and ventral views are showing activation of Wnt/β-catenin signaling 
in the head, trunk, eye lens and jaw for both the control as well as MO2-injected embryos. Note 
that expression of GFP could not be detected in the heart (arrows). Scale bars: 50 µm. 
 
4.18  Npnt does not signal through integrin α8 
Recently it has been shown that Npnt acts during kidney  development as a 
ligand of integrin α8β1 regulating cell migration (85, 87). To determine whether 
integrin α8β1 might act also during heart development as a receptor for Npnt, 
we determined integrin α8 expression by in situ hybridization in the zebrafish 
heart.  integrin  α8  was  strongly  expressed  in  jaw,  pectoral  fin,  eye  lens  and 
other tissues but not detectable in the heart (Figure 4.19). These data indicate 
that  Npnt  does  not  signal  through  integrin  α8  during  zebrafish  heart 
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Figure  4.19:  itga8  is  not 
expressed  during  early 
heart  development.  (A-I) 
Brightfield  images  of  52  hpf 
WT  embryos  after  whole-
mount  in  situ  hybridization 
with  probes  against  itga8. 
Ventral and dorsal views of 36 
hpf,  48  hpf  and  60  hpf 
embryos  are  showing 
expression of itga8 in several 
tissues  like  jaw,  pectoral  fin 
and  eye  lens  (arrowheads). 
Expression of itga8 could not 
be  detected  in  the  heart 
(arrows). Scale bars: 50 µm. 
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5.  Discussion and outlook 
Our data identify Npnt as a novel regulator of early heart development. Several 
lines of evidence support this conclusion. First, Npnt knockdown in zebrafish 
causes  ≈90%  lethality  at  7  dpf.  Second,  Npnt  morphant  hearts  were 
characterized  by  an  expanded  AV  canal,  increased  cardiac  jelly,  impaired 
trabeculation and failure of proper valve leaflet formation at the AV boundary. 
Third, Has2 knockdown rescued the endocardial phenotype in Npnt morphants. 
Fourth,  chemical  inhibition  of  BMP  signaling  rescued  AV  canal  extension  in 
Npnt  morphants  in  respect  to  myocardium  as  well  as  endocardium.  In 
summary,  our  data indicate  that Npnt regulates the  differentiation of the AV 
segment via the BMP4-Has2 signaling cascade. 
 
5.1  The ECM is critical for valve development 
Previously,  it  has  been  shown  that  regionally  specific  interactions  of  the 
myocardium  and  endocardium  are  required  to  initiate  the  formation  of 
prevalvular cell differentiation (23, 123, 124). Changes in the composition or 
amount  of  the  ECM  can  interfere  with  valve  formation.  cspg2  and  has2 
knockout  mice  exhibit  reduced  amount  of  cardiac  jelly  and  fail  to  form 
endocardial cushions (53, 60). However, AV cushion development appeared 
normal in fibulin1 knockout mice (125). Here, we discovered Npnt as a novel 
component  of  the  cardiac  ECM  during  early  development.  Surprisingly,  the 
knockdown  of  Npnt  caused  in  contrast  to  the  above-mentioned  studies  an 
increase in cardiac jelly throughout the anteroposterior extent of the heart.  
  The increase in cardiac jelly and possibly the change in the composition 
of the cardiac jelly might be responsible for the failure of Npnt morphants to 
form proper valves. The expanded cardiac jelly in Npnt morphant hearts might 
act  as  an  inhibitor  of  signaling  as  the  ECM  modulates  the  activity, 
bioavailability, or presentation of growth factors to cell surface receptors (114). 
It  has  for  example  been  shown  that  increased  expression  of  versican  and 
associated proteins results in an increase in the pericellular matrix of cells, an 
expansion of the ECM and a change of the viscoelastic nature of the ECM. 
Such mechanical changes are known to have dramatic effects on the tension 
exerted on cells and the traction forces generated by the cell. These forces are 
known to impact signaling influencing for example migration (114-116). Thus, Discussion    77 
Npnt knockdown might cause a change of the viscoelastic nature of the ECM 
that hinders AV endocardial cells to migrate into the ECM at the AV boundary 
preventing proper valve leaflet formation. In the future it will be important to 
analyze the composition of the cardiac jelly in Npnt morphants. 
 
5.2  Npnt does not regulate Wnt signaling 
Npnt appears in general to act both as a structural protein as well as a ligand 
that induces signaling. First, it is known that Npnt acts as a ligand for integrin 
α8β1  regulating  migration  during  kidney  development  (87).  Second,  Npnt 
contains EGF domains that have been shown to be required for Npnt-induced 
osteoblast differentiation (126). Similarly, it has been suggested that the EGF 
domains of Versican can bind and activate growth factor receptors (127, 128). 
The concept that Npnt acts as a ligand during heart development could also 
explain  why  Npnt  knockdown  affects  only  the  AV  boundary  although  it  is 
expressed throughout the myocardium.  
  One way to gain insight into how Npnt regulates valve development is to 
compare the phenotype of Npnt morphants with existing phenotypes of other 
morphants  or  mutants.  Interestingly,  the  Npnt  morphant  phenotype  shares 
some characteristics with the zebrafish apc mutant in which the Wnt signaling 
pathway  is  constitutively  activated.  apc  mutant  and  Npnt  morphant  hearts 
appear  normal  at  36  hpf.  Between  37  and  45  hpf  several  genes  including 
bmp4,  has2,  cspg2  and  notch1b  become  restricted  to  the  AV  canal.  This 
restriction  is  in  both  morphants  impaired.  Moreover,  compared  to  wild  type 
embryos apc mutant and Npnt morphant embryos form excessive cardiac jelly 
and fail to loop. As bmp4, versican  and has2 are purportedly transcriptional 
targets  of  the  Wnt/β-catenin  signaling  pathway  (121,  122),Npnt  could  be  a 
target of this cascade or may signal through the Wnt signaling cascade. Thus, it 
is important to  determine  the  activity  of  the Wnt  signaling  pathway  at  2  dpf 
when Npnt exhibits its function. Hurlstone et al. have shown that in wild type 
embryos Wnt/β-catenin signaling is restricted at the AV boundary at 72 hpf. In 
contrast,  in  apc  mutant  this  signaling  becomes  activated  throughout  the 
anteroposterior extent of the heart (49). Unfortunately, they do not report data 
regarding Wnt/β-catenin signaling at 2 dpf. Our analysis revealed that there is 
no activation of Wnt expression in the heart of Tg(TOP:GFP)
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dpf. In addition, Npnt knockdown did not induce ectopic activation of Wnt in 
Tg(TOP:GFP)
w25 embryos in the heart at 2 dpf. These findings indicate that the 
observed earliest cardiac phenotype of Npnt morphants at 52 hpf is not due to 
the ectopic avtivation of Wnt/β-catenin signaling.  
 
5.3  Npnt signals through the BMP4-Has2 axis 
Our  experimental  outcomes  suggest  that  Npnt  is  required  to  restrict  the 
expression of cspg2 and has2. Previously, it has been shown that has2 plays 
an essential role in the formation of cardiac jelly and initiation of cardiac valve 
development via hyaluronan synthesis (53). Our has2 knockdown experiments 
in wild type embryos confirmed the role of has2 in the formation of cardiac jelly 
and  prevalvular  AV  endocardial  cell  differentiation  in  zebrafish.  Importantly, 
has2  knockdown  in  Npnt  morphants  rescued  the  observed  endocardial 
phenotype  and  demonstrates  that  Npnt  controls  AV  endocardial  cell 
differentiation by regulating has2 expression. 
has2 knockdown in Npnt morphants neither rescued ectopic expression 
of bmp4 nor cspg2. Thus, there appears to be no cross talk between BMP4 and 
Has2  or  BMP4  is  an  upstream  regulator  of  has2  expression  and  the 
endocardial phenotype is a consequence of the ectopic myocardial expression 
of  bmp4.  Previously,  BMP  signaling  has  been  shown  to  regulate  has2 
expression  (109)  but  the  data  are  controversial  (118).  Inhibition  of  BMP 
signaling  in  Npnt  morphants  reverted  the  endocardial  phenotype  to  normal, 
partially rescued the AV canal extension defect and reduced has2 and cspg2 
gene  expression.  Our  data  indicate  that  Npnt  is  required  to  restrict  the 
expression of BMP4 and that expanded bmp4 expression in Npnt morphants 
causes increased expression of cspg2 and has2 which explains the expansion 
of the AV canal as well as the increase in cardiac jelly. Thus, it appears likely 
that  BMP4  is  an  upstream  regulator  of  has2  expression  and  that  the 
endocardial phenotype is a consequence of the ectopic myocardial expression 
of bmp4. 
In wild type embryos dorsomorphin did not affect basal expression of the 
genes important for AV canal differentiation. This might be due to the fact that 
dorsomorphin  treatment  resulted  only  in  partial  inhibition  of  BMP-Smad 
signaling  and  that  complete  inhibition  could  not  be  achieved  even  at  higher Discussion    79 
dorsomorphin  concentrations  (Figure  4.16).  Another  possible  explanation  is 
that  endogenous  BMP  signaling  is  redundant  at  the  AV  canal.  To  further 
substantiate the importance of BMP4 one could utilize the transgenic zebrafish 
line tg(hsp70:noggin3) that expresses the specific BMP inhibitor noggin3 under 
the  control  of  hsp70  promoter  and  allows  efficient  inhibition  at  distinct  time 
points  (129).  This  transgenic  line  could  also  be  used  to  rescue  the  cardiac 
phenotype of the Npnt morphant. Taken together, our data demonstrate that 
Npnt  is  an  upstream  regulator  of  BMP  signaling.  Moreover,  these  findings 
suggest that ectopic BMP signaling regulates has2 and cspg2 expression. 
Our  data  have  identified  Nephronectin  as  an  upstream  regulator  of 
BMP4  signaling,  however,  the  underlying  mechanism  remains  unclear.  For 
example, one would assume for an inhibitor of BMP4 expression or signaling to 
be expressed only in the chambers but not in the AV canal itself. Based on our 
experimental  outcomes  and  others  published  reports  we  hypothesize  two 
regulatory mechanisms for how Npnt regulates BMP4 signaling: 1) Npnt binds 
to a chamber-specific receptor inhibiting bmp4 expression. 2) Npnt prevents the 
diffusion and thus the bioavailability to BMP4. 
 
5.3.1 Receptor-mediated inhibition of bmp4 expression 
One  possible  regulation  of  BMP  signaling  in  the  chambers  is  a  receptor-
mediated inhibition by Npnt (Figure 5.1). 
 
Figure  5.1:  Proposed  model  of  the 
regulatory  role  of  Npnt  via  its  potential 
receptor. Npnt activates a receptor expressed 
only  in  the  chamber  myocardium  repressing 
BMP4 signaling. 
 
 
 
 
 
 
Recently it has been shown that Npnt acts during kidney development 
as a ligand of integrin α8β1 regulating cell migration (85, 87). However, during 
the time of npnt expression in the zebrafish heart we did not detect integrin α8 Discussion    80 
expression  by  in  situ  hybridization  in  the  zebrafish  heart  whereas  strong 
expression was detected in jaw, pectoral fin, eye lens and other tissues. These 
data  indicate  that  Npnt  does  not  signal  through  integrin  α8  during  zebrafish 
heart development. However, Nephronectin can bind also other integrins like 
integrin αV (vitronectin receptor) (85). Interestingly, integrin αV is expressed in 
the heart during early zebrafish development (130). Thus integrin αV could be a 
potential  receptor  for  Npnt  signaling.  To  validate  this  hypothesis  it  will  be 
important  to  determine  the  spatiotemporal  expression  pattern  of  integrin  αV 
around the time of npnt expression as well as to investigate the consequences 
of  integrin  αV  knockdown  for  zebrafish  heart  development.  If  Npnt  indeed 
signals  through  integrin  αV  to  inhibit  BMP  signaling  it  will  be  important  to 
identify which subtype of β integrins is utilized, to elucidate the downstream 
signaling and whether this mechanism plays a role in other developing organs. 
  
5.3.2 Npnt  controls  BMP4  bioavailability  by  limiting  its 
diffusion 
Npnt might exert its functions via modulating the bioavailability of BMP4. We 
hypothesize that Npnt is required for the establishment of an ECM that limits 
the diffusion rate of BMP4 (Figure 5.3).  
 
Figure  5.3:  Proposed 
model  of  the  regulatory 
role  of  Nephronectin  by 
inhibiting  its  diffusion. 
BMP4  can  bind  with  the 
glycosylated  anionic 
domain  of  Npnt  and  thus 
might prevents its  diffusion 
towards the chambers. 
 
A limited diffusion rate would cause an increased concentration of BMP4 
at the proximity of the expressing cell limiting BMP4 to signal in an autocrine 
fashion.  Depletion  of  Npnt  would  prevent  BMP4  retention  resulting  in  the 
diffusion of BMP4 towards the chambers switching from autocrine to paracrine 
signaling.  As  the  chambers  also  express  BMP  receptors  (131)  BMP4  might Discussion    81 
reprogram  chamber  cells  into  AV  canal  cells.  Ectopic  expression  of  BMP4 
might be due to an autoregulation of BMP4 gene transcription (132).  
  Osteoblast  differentiation  and  valve  formation  share  some  regulatory 
mechanisms (133). Thus, the osteoblast differentiation system might provide 
arguments to support our hypothesis of BMP4 diffusion control. Importantly, it 
has  been  shown  that  Npnt  is  highly  expressed  during  early  osteoblast 
differentiation  and  Npnt  overexpression  promotes  osteoblast  differentiation 
(94). In addition, BMPs  signaling  plays  an important role in  early osteoblast 
differentiation  (40).  Interestingly,  osteoblast  differentiation  is  dependent  on 
ECM deposition, which sequesters BMPs to facilitate BMP receptor activation 
to induce differentiation (134).  
  So  far  it  has  only  been  shown  that  Npnt  expression  correlates  with 
BMP4  signaling.  However,  the  fact  that  Npnt  contains  a  mucin-like  repeat 
domain indicating glycosylation (87) suggests that Npnt can bind and sequester 
cytokines,  growth  factors  and  morphogens  regulating  their  bioavailability  to 
their cell surface receptors as shown previously for several other proteoglycans 
(135). The data by Sato et al. further substantiate that Npnt is glycolysated as 
they  have  shown  that  the  size  of  the  secreted  Npnt  on  a  reducing 
polyacrylamide gel is around 120 kDa instead of the predicted size of 61 kDa 
(85).  
  Osteoblast differentiation can be studied in vitro utilizing the M3TC3 cell 
line. In future experiments it will be important to confirm the accumulation of 
BMP4  on  the  cell  surface  and  to  manipulate  the  expression  of  Npnt. 
Knockdown  experiments  should  reveal  whether  BMP4  accumulation  and 
signaling depends on Npnt. Overexpression experiment will show whether Npnt 
is sufficient to  retain  BMP4  on  the  cell surface.  In addition, it  is  possible to 
determine the role of Npnt regarding BMP signaling in the heart also by utilizing 
the well-established mouse AV canal explant culture system (48). 
 
5.4  Npnt signals through growth factor receptors 
Npnt has several Ca
2+ dependent EGF-like repeat domains and it has been 
suggested that Npnt can induce signaling through its EGF-like repeats that are 
required  for  Npnt-induced  osteoblast  differentiation  (94).  Thus,  Npnt  might 
activate or modulate growth factor receptor signaling during heart development. Discussion    82 
  We hypothesize that Npnt affects ErbB receptor signaling. Several lines 
of  evidence  support  this  hypothesis:  First,  signaling  via  ErbB  receptors  is 
important for cardiac valve development and ventricular trabeculation (28, 136, 
137). Second, Ca
2+ dependent EGF-like repeats of several proteins like EGF, 
TGF-α,  heparin  binding  EGF,  amphiregulin,  epiregulin,  and  neuregulin 
(heregulin-1) bind to the extracellular domain of ErbB receptors and activate its 
downstream  signaling (138). Similarly, the  EGF-like repeats  of Versican can 
bind and activate ErbB receptors (127, 128).  
  The ErbB receptor family consists of four different type-I tyrosine kinase 
receptors (ErbB1 to ErbB4 also known as HER1 to HER4). For activation of 
downstream  signaling  ErbB  receptor  homodimerise  or  heterodimerise  with 
other  ErbB  family  members  in  the  presence  of  a  ligand  (138).  In  mice 
myocardial, endocardial as well as invading mesenchymal cells express ErbB2 
during cardiac development. Invading mesenchymal cells and a subpopulation 
of endocardial cells are predominantly ErbB3-positive but ErbB4-negative (28, 
137).  In  contrast,  the  myocardium  is  ErbB4-positive  (around  E9.5-E11)  (28, 
136). Using AV canal explant cultures it has been demonstrated that cushion 
mesenchyme  transformation  in  the  AV  canal  of  ErbB2
-/-  and  ErbB3
-/-  mice 
embryos is significantly reduced. In contrast, EMT was not affected in ErbB4
-/- 
mice. However these mice exhibit myocardial differentiation and trabeculation 
problems  (28,  136).  These  data  suggest  that  signaling  via  ErbB2/ErbB3 
heterodimers is important for cardiac valve development and via ErbB2/ErbB4s 
for ventricular trabeculation.  
  The phenotype of Npnt morphants is very similar to the phenotypes of 
ErbB2
-/- and ErbB3
-/- mice. Thus, it will be important to determine in the future 
the  spatiotemporal  expression  pattern  of  ErbB2-4  during  early  heart 
development  in  wild  type  and  Npnt  morphant  zebrafish  (30  to  80  hpf).  In 
addition, it  will be  interesting to perform  overexpression experiments in  vitro 
and in vivo to determine the affect of Npnt on downstream signaling of ErbBs 
(activation of ERK1/2 and PI3 kinase cascade). 
 
5.5  Npnt depletion does not affect cardiomyocyte number 
Our data demonstrate on a molecular and cellular level that the AV canal in 
Npnt morphants contains around double as many cells as the AV canal in wild Discussion    83 
type  embryos.  Where  do  these  cells  come  from?  There  are  two  possible 
explanations. One is that Npnt depletion triggers increased proliferation of AV 
canal cells or that Npnt depletion results in more cells differentiating into AV 
canal  cells.  In  case  that  Npnt  regulates  AV  canal  cell  proliferation  the  total 
number of cardiomyocytes should increase. However, our data suggest that the 
total number of cardiomyocytes as well as the number of atrial cardiomyocytes 
is  unaffected.  Based  on  these  data,  one  may  conclude  that  Npnt  depletion 
results in an increased number of cells differentiating into AV canal cells on the 
expense  of  chamber  cells.  This  suggests  that  Npnt  morphants  exhibit  a 
patterning  phenotype.  However,  it  will  be  important  in  future  experiments  to 
further substantiate this conclusion as the applied technique to determine cell 
numbers has limitations. First, the addition of cell numbers is relatively small to 
the total number of cardiomyocytes in the heart. Second, the variation in the 
cardiomyocyte number of individual hearts is relatively high compared to the 
increase in AV canal cells in Npnt morphants. Third, AV canal cells in wild type 
embryos are difficult to count, as their cell density is very high. In contrast, the 
cell density of AV canal cells in the elongated and less looped Npnt morphant 
hearts  is  lower.  This  difference  might  result  in  a  miscalculation  of  the  cell 
numbers. Therefore, a detailed cell cycle analysis should be performed in the 
future. 
 
5.6  Conclusion 
Our  data  establish Nephronectin as a novel regulator of heart  development. 
Our data suggest that Npnt is required as a regulator of BMP4-Has2 signaling 
to restrict AV canal differentiation and cardiac jelly swelling at the prevalvular 
stage. Furthermore, our data indicate that Npnt is also involved in trabeculation.  
  In the future it will be important to determine how Npnt regulates BMP4 
signaling and whether it affects additional signaling pathways. We hypothesize 
that  Npnt  regulates  heart  development  on  several  levels  by  modulating  the 
bioavailability of growth factors and by acting as a ligand for integrin receptors 
as  well  as  for  growth  factor  receptors.  It  might  also  be  possible  that  Npnt 
modulates  receptor  signaling  by  bringing  via  EGF-like  repeats  and  RGD 
domain ErbB receptors and integrins in close proximity. 
  The finding that nephronectin is required for proper heart development is Discussion    84 
important for several reasons. To our knowledge, this is the first evidence that 
Nephronectin  is  transiently  expressed  in  the  heart.  Second,  this  is  the  first 
evidence that Nephronectin regulates valve formation and trabeculation. Third, 
our data establish Nephronectin as a novel regulator of BMP4 and adds novel 
data on the dispute whether BMP4 is an upstream regulator of Has2. Fourth, 
we  demonstrate  that  Has2  plays  a  major  role  in  the  differentiation  of 
endocardial cells in the AV canal. Finally, the information provided by this study 
may  be  of  medical  relevance.  Defects  in  cardiac  valves  and  associated 
structures account for 25% to 30% of all cardiovascular anomalies and their 
underlying cause is often unknown. Summary    85 
6.  Summary 
 
It has been estimated that about 1% of live births carry severe congenital heart 
defects  and  20-30%  among  them  have  valve  malformations  (3).  Despite  its 
medical importance the underlying cause of many valvular diseases remains 
undiscovered. Thus, it is important to identify genes that play a crucial role in 
cardiac valve formation and maturation. 
A temporal RNA expression analysis of heart development suggested 
that the extracellular matrix protein Nephronectin might be a novel regulator of 
valve development and/or trabeculation. Nephronectin is transiently expressed 
during  rat  heart development at  the time  of heart valve morphogenesis  and 
trabeculation.  Moreover,  the  extracellular  matrix  is  known  to  be  crucial  for 
organogenesis. It is a complex, dynamic and critical component that regulates 
cell  behavior  by  modulating  the  activity,  bioavailability,  or  presentation  of 
growth factors to cell surface receptors. 
  In order to verify the hypothesis that Nephronectin is a novel regulator of 
valve  formation  and/or  trabeculation  the  zebrafish  was  chosen  as  model 
system. Females are able to spawn at intervals of 5 days laying hundreds of 
eggs  in  each  clutch.  Development  progresses  rapidly  with  precursors  to  all 
major organs appearing within 36 hours post fertilization. Zebrafish embryos 
develop  externally,  are  translucent  and  continue  to  grow  for  several  days 
despite developing severely malformed, non functional hearts. In addition, gene 
expression can be easily modulated.  
  During  the  present  study  it  has  been  shown  that  Nephronectin 
expression is correlated to valve development and trabeculation. Morpholino-
mediated  knockdown  of  Nephronectin  in  zebrafish  caused  failure  of  valve 
formation  and  trabeculation  resulting  in  >  85%  lethality  at  7  days  post 
fertilization.  
  Cardiac valve formation is initiated at the junction of atrium and ventricle 
and  is  characterized  by  extracellular  matrix  deposition  and  endocardial  cell 
differentiation. In accordance with the above-described phenotype the earliest 
observed abnormality in Nephronectin morphants was an extended tube like 
structure  at  the  atrio-ventricular  boundary.  In  addition,  the  expression  of 
myocardial genes involved in cardiac valve formation (cspg2, fibulin1, tbx2b, 
bmp4)  was  expanded  and  endocardial  cells  along  the  extended  tube  like Summary    86 
structure exhibited characteristics of atrio-ventricular cells (has2, notch1b and 
Alcam  expression,  cuboidal  cell  shape).  Inhibition  of  has2  in  Nephronectin 
morphants  rescued  the  endocardial  but  not  the  myocardial  expansion.  In 
contrast, diminishment of BMP signaling in npnt morphants resulted in reduced 
ectopic  expression  of  myocardial  and  endocardial  atrio-ventricular  markers. 
Taken  together,  these  results  identify  Nephronectin  as  a  novel  upstream 
regulator  of  BMP4-HAS2  signaling  playing  a  crucial  role  in  atrio-ventricular 
canal differentiation. References    87 
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Npnt amino acid sequence homology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  A1:  Amino  acid  sequence  demonstrating  Npnt  protein  homology  among  zebrafish, 
mouse, rat and human.  Appendices    96 
Table A1: Sequential events during zebrafish heart 
development 
Events  Developmental time-point 
Initiation of Cardiogenesis  Early blastula (2.75 hpf/512 cells) 
Cardiac  progenitors  located  at    the 
blastoderm margin 
40 % epiboly (5 hpf) 
Precardiac cells involute  and migrate 
towards animal pole 
Gastrulation (5.5 hpf to 8 hpf) 
Progenitors  are  reached  embryonic 
axis and form a part of ALPM (those 
celss are NKX2.5 positive) 
6-8 somite stage (11.5 hpf) 
NKX2.5  positive  cells  are  migrated 
medially   
10-16 somite stage (14-16 hpf) 
Initiation of myocardial differentiation 
(  Cells  exhibit  cmlc2  expression  and 
ventricular  cardiomyocytes  are 
expressed vmhc) 
13-14 somite stage (15 hpf) 
Atrial  progenitors  exhibit  amhc 
expression 
19 somite stage (17 hpf) 
Cardiomyocyte progenitors are formed 
a pair of bilateral complete tube 
16 somite stage (16 hpf) 
Cardiac fusion  18 somite stage 
Cardiac cone is formed  21 somite stage (19 hpf) 
Cardiac tube is formed   27 somite stage (22 hpf) 
Initiation of cardiac contraction  27 somite stage (22 hpf) 
Organization  of  the  atrial 
cardiomyocytes is completed  
24 hpf 
Initiation  of  cardiac  ballooning  and 
looping morphogenesis (visibly distinct 
ventricular and atrial chambers)  
30 hpf 
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Events  Developmental time-point 
Initiation  of  endocardial  cell 
differentiation  and  cardiac  jelly 
swelling at AVC 
36 hpf 
Visible Proepicardial organs (PEO)  50 hpf 
Cellular migration of the PEO  3 dpf to 4 dpf 
Ventricular trabeculation initiation  3 dpf 
Every  part  of  the  adult  heart 
appearance 
5 dpf 
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Zusammenfassung 
Nephronectin reguliert die Herzklappenentwicklung über den 
BMP4-HAS2 Signaltransduktionsweg im Zebrafisch 
 
Einleitung 
Angeborene Herzerkrankungen sind weltweit die häufigste Todesursache aller 
auf  Geburtsfehler  zurückzuführender  Todesfälle.  Ungefähr  1%  aller 
Lebendgeburten  ist  betroffen  (1).  Die  Ursache  für  die  meisten  dieser 
Erkrankungen ist bisher unklar. Angesichts der hohen Morbidität und Mortalität 
angeborener  Herzerkrankungen  ist  es  wichtig  deren  Krankheitsursache  zu 
bestimmen.  Dafür  ist  ein  detailliertes  Wissen  der  Entwicklung  des  Herzens 
erforderlich.  
  Angeborene  Herzklappenfehler  stellen  mit  20  bis  30%  die  häufigsten 
angeborenen Herzerkrankungen dar (3) Aus diesem Grund beschäftigt sich die 
vorliegende Doktorarbeit mit der Aufklärung molekularer Mechanismen, welche 
die Herzklappenentwicklung regulieren. In dieser Arbeit wurde der Zebrafisch 
als Modellsystem gewählt. 
 
Herzentwicklung 
Die Herzentwicklung im Zebrafisch beginnt 2,75 Stunden nach der Befruchtung 
(hours post fertilization, hpf) im Blastulastadium. Die Kardiogenese erfolgt dann 
über  eine  komplexe  Serie  von  Schritten,  die  anfangs  vor  allem 
Differenzierungs- und Migrationsprozesse beinhalten. Das Herz entwickelt sich 
aus  dem  Herzblastem  in  der  viszeralen  Mesodermschicht  der  rechten  und 
linken  Seite  zunächst  getrennt  voneinander.  Später  vereinigen  sich  diese 
beiden  Herzanlagen  in  der  Mittellinie  und  bilden  den  Herzschlauch.  Dieser 
beginnt  um  22  hpf  zu  kontrahieren.  Die  hämodynamischen  Veränderungen 
induzieren  regional  spezifische  Genexpression,  die  von  entscheidender 
Bedeutung für  die Herzklappenentwicklung und Trabekulierung sind  (61, 62) 
(65) (66, 69) (72, 73). 
  Der  Herzschlauch  besteht  aus  dem  Endokard  und  dem  Myokard 
(Muskelschicht), die durch eine zellfreie Schicht extrazellulärer Matrix (EZM), 
der  Herzgallerte,  getrennt  wird.  Der  Schlauch  wächst  und  bildet  die 
Herzschleife,  in  der  Ventrikel  und  Atrium  um  30  hpf  unterschieden  werden Appendices    101 
können (70, 71). Am dritten Tag nach Befruchtung sind vier Herzkammern zu 
erkennen  (Atrium,  Ventrikel,  Sinus  Venosus,  Bulbus  Arteriosus),  die  durch 
Einschnürungen  voneinander  getrennt  sind  (77,  78).  Zu  diesem  Zeitpunkt 
beginnt  die  Trabekulierung,  d.h.  es  bilden  sich  kleine  Gruppen  ventrikulärer 
Herzmuskelzellen, die aus der Herzmuskelwand in die EZM ragen (79). 
 
Herzklappenentwicklung 
Alle Wirbeltiere besitzen Herzklappen, um den Blutkreislauf zu regulieren und 
einen Rückstrom des Blutes in die falsche Richtung zu verhindern. Um 30 hpf 
sind  ventrikuläre  Herzmuskelzellen  kubisch  während  Herzmuskelzellen  des 
Atriums  und  Endokardzellen  squamös  (flach)  sind.  Herzmuskelzellen  am 
Übergang  vom  Atrium  zum  Ventrikel,  dem  sogenannten  atrio-ventrikulären 
(AV)-Kanal, haben keine besondere Form (81)  
  Die Herzklappenentwicklung beginnt im AV-Kanal um 36 hpf mit dem 
Anschwellen  der  EZM.  Zu  dem  beginnen  sowohl  die  Herzmuskelzellen  als 
auch die Endokardzellen im AV-Kanal zu differenzieren. Zuerst differenziert nur 
eine Reihe von 12 Endokardzellen, die zusammen mit den Herzmuskelzellen 
EZM-Komponenten exprimieren. Dies führt zum Anschwellen der EZM im AV-
Kanal. Die Anzahl differenzierter Endokardzellen nimmt stetig zu und am 2ten 
Tag  nach  der  Befruchtung  kleiden  5  bis  6  Reihen  differenzierter 
Endokardzellen den AV-Kanal aus. Diese Zellen sind charakterisiert durch ihre 
kubische  Form  und  die  Expression  des  Zelladhäsionsproteins  Alcam  (Dm-
grasp).  Während  der  Differenzierung  des  AV-Kanals  und  der 
Herzlappenbildung  werden  Gene,  die  zuvor  im  gesamten  Herzschlauch 
exprimiert wurden, nur noch im AV-Kanal exprimiert (has2, bmp4, cspg2, tbx2 
and  notch1b).  Um  60  hpf  beginnen  die  differenzierten  AV-Endokardzellen 
Herzklappenvorläufer zu bilden (81) 
   
Nephronectin 
Wir haben kürzlich Nephronectin (Npnt) als transient exprimiertes Protein in der 
Herzentwicklung  der  Ratte  identifiziert.  Seine  Expression  korreliert  mit  der 
Herzklappenentwicklung.  Npnt  ist  ein  EZM-Protein  mit  folgender 
Domänenstruktur: N-terminales Signalpeptid, Ca
2+-abhängigen EGF-ähnichen 
Domänen,  Mucin-ähnliche  Domäne,  RGD  Sequenz  und  C-terminale  MAM Appendices    102 
Domäne.  Diese  Struktur  weißt  daraufhin,  dass  es  sich  um  ein  sekretiertes, 
vermutlich glykolisiertes Protein mit adhäsiven Eigenschaften handelt, das mit 
Wachtumsfaktoren,  Wachstumsfaktorrezeptoren  und  Integrinen  interagieren 
kann. Mehrere Studien legen nahe, dass Npnt eine wichtige Funktion in der 
Nierenentwicklung  und –regeneration spielt sowie in der Differenzierung von 
Osteoblasten. Funktionell scheint es eine wichtige Funktion in der Zellmigration 
zu haben (85-88) (91) (90) (93) (94).  
 
Problemstellung 
Um  die  Entwicklung  des  Herzens  besser  zu  verstehen  hat  Dr.  Engel  eine 
Expressionsstudie  durchgeführt,  welche  die  Expression  von  28000  Genen 
während der Herzentwicklung der Ratte vom embryonalen Tag E11 bis zum 
postnatalen  Tag  P10,5  im  Abstand  von  12  Stunden  beschreibt.  Diese 
Expressionsdaten  verbunden  mit  einem  bioinformatischen  Ansatz  und  dem 
Wissen über  zeitliche Veränderungen der  Herzmorphologie  resultierte in  der 
Hypothese: „Nephronectin ist ein neuer Regulator der Herzklappenentwicklung 
und/oder der Trabekulierung“.  
  Ziel der Arbeit war die Verifizierung dieser Hypothese. Als Modellsystem 
wurde  der  Zebrafisch  gewählt,  da  Zebrafische  alle  5  Tage  mehrere  hundert 
Embryonen produzieren, diese sich extern  entwickeln, transparent sind, sich 
mehrere  Tage  ohne  funktionierendes  Herz  entwickeln  und  die 
Herzklappenentwicklung bereits nach 36 hpf initiiert wird. Darüber hinaus lässt 
sich  die  Expression  bzw.  Funktion  von  Genen  und  Proteinen  leicht 
manipulieren. 
 
Ziel 1:  Bestimmung  des  räumlich-zeitlichen  Expressionsmusters  von  Npnt 
während der Herzentwicklung im Zebrafisch. 
Ziel 2:  Morpholino-basierter  Knockdown  von  Npnt,  um  dessen  Funktion 
während der Herzentwicklung im Zebrafisch zu bestimmen. 
Ziel 3:  Identifizierung  der  Signaltransduktionswege,  die  Npnt  während  der 
Herzentwicklung nutzt, um die Herzklappenentwicklung zu steuern. Appendices    103 
Ergebnisse 
Anhand  von  RT-PCR  Experimenten  konnte  bestätigt  werden,  dass  npnt 
transient  im  Rattenherzen  während  der  Herzklappenbildung  und  der 
Trabekulation exprimiert  wird (E11 to  E17). Das Protein  Npnt  konnte mittels 
Antikörperfärbungen  im  Myokard  aber  nicht  im  Endokard  oder  Epikard  im 
Herzen  von  Rattenembryonen  (E14)  detektiert  werden. 
Zellfraktionierungsexperimente  deuten  darauf  hin,  dass  npnt  sowohl  in 
Herzmuskelzellen  als  auch  in  den  andern  Myokardzellen  (z.B.  Fibroblasten) 
exprimiert wird. 
  Die  Expression  im  Zebrafisch  wurde  mittels  in  situ  Hybridisierung 
bestimmt. Um 24 hpf wurde npnt am Schwanzende, im Kopf, am hinteren Ende 
des Darms und dem Endoderm der Pharynx (Rachen) detektiert. 34 hpf wurde 
die  Expression  nach  wie  vor  im  Kopf  und  zusätzlich  in  der  Region  der 
Nierenvorläufer  beobachtet.  Expression  im  Herzen  wurde  erst  um  44  hpf 
detektiert. Zu diesem Zeitpunkt war npnt auch in den Schlundtaschen und im 
Mandibularknorpel  exprimiert.  Herzexpression  war  auch  noch  nach  48  hpf 
nachweisbar,  konnte  aber  um  53  hpf  nicht  mehr  detektiert  werden. 
Untersuchungen  an  Schnitten  zeigten,  dass  npnt  im  gesamten  Herzen 
exprimiert wird. 
  Um  die  Funktion  von  Npnt  für  das  Herz  zu  bestimmen,  wurde  die 
Expression von npnt mittels sogenannter Morpholinos unterdrückt. Morpholinos 
sind Oligonukleotide, die an prä-mRNA binden und das Splicing inhibieren bzw. 
an das Translationsstartkodon ATG binden und die Translation inhibieren. In 
dieser  Studie  wurden  drei  Morpholinos  eingesetzt.  Western  Blot  Versuche 
haben gezeigt, dass alle drei Morpholinos die Expression von Nephronectin auf 
Proteinebene effizient inhibieren. 
  Mit  Hilfe  dieser  Morpholinos  konnte  gezeigt  werden,  dass  der  Npnt 
Knockdown  7  Tage  nach  Befruchtung  zu  89%  ±  7.9%  lethal  ist.  Der  erste 
offensichtliche  Phänotyp  ist  ein  kardiales  Ödem  um  75  hpf.  Die 
Herzklappenbildung und Trabekulierung  war in 86% ± 3.9% der Zebrafische 
um 110 hpf stark gestört und > 30% dieser Fische zeigten keinerlei Hinweise 
auf  eine  Herzklappenentwicklung.  Zudem  wurde  beobachtet,  dass  die 
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  Eine  nähere  Analyse  unter  zur  Hilfenahme  transgener  Fischlinien,  in 
denen die  Zellmembran  bzw. die  Zellkerne von Herzmuskelzellen mit einem 
Fluorochrom markiert sind, zeigte dass der AV-Kanal in npnt Morphanten um 
52 hpf verlängert war. Anhand von Ko-Injektionen von Morpholinos und npnt 
mRNA  konnte  gezeigt  werden,  dass  dieser  Phänotyp  spezifisch  ist.  Die 
injizierte  mRNA  wird  nicht  von  den  Mopholinos,  die  Splicing  inhibieren, 
beeinträchtigt und wird daher genutzt, um zu testen welche Nebeneffekte die 
eingesetzten  Morpholinos  haben.  Die  Injektion  von  30  pg  npnt  mRNA  hatte 
keinen  Effekt  auf  die  Herzentwicklung  in  Wildtyp  Fischen  konnte  aber  auch 
nicht den Effekt der Morpholinos beeinflussen. Im Gegensatz dazu resultierte 
die Injektion von 50 pg npnt mRNA in einer Reduzierung des AV-Kanaldefekts 
in den  Morphanten. 40% ±  2.33% der Embryonen  wiesen nach  Ko-Injektion 
einen AV-Kanal normaler Länge im Gegensatz zu 11% ± 2.0% der Embryonen 
nach Morpholino-Injektion. Zu dem wurde der Effekt in den übrigen Embryonen 
gemildert. Injektionen von 80 pg npnt mRNA resultierte in starken Defekten in 
Wildtyp Embryonen.  
  Nach der Charakterisierung des Phänotyps auf morphologischer Ebene 
wurden  als  nächstes  molekulare  und  zelluläre  Veränderungen  im  Myokard 
untersucht.  In  situ  Hybridisierungsexperimente  um  52  hpf  zeigten,  dass  die 
Expression  der  spezifischen  AV-Kanalmarker  cspg2  (versican  Homolog  im 
Zebrafisch),  bone  morphogenetic  protein  4  (bmp4)  und  fibulin1  in  den 
Morphanten expandiert ist. Zu dem wurde in den Morphanten ektopische cspg2 
Expression  im  Einflusstrakt  detektiert.  Die  Expression  der  Herzkammer-
spezifischen Gene vmhc und amhc waren nicht beeinflusst. Untersuchungen 
des Endokards um 52 hpf zeigten, dass die Expression der spezifischen AV-
Kanalmarker  notch1b  und  Alcam  expandiert  ist.  Detaillierte  Untersuchungen 
mittels konfokaler Lasermikroskopie zeigten, dass Morphanten anstatt 5 bis 6 
Reihen  8  bis  12  Reihen  an  Alcam-positiven  Endokardzellen  besitzen.  Diese 
Daten zeigen, dass Npnt Knockdown in einer Verlängerung des AV-Kanal auf 
morphologischer, zellulärer und molekularer Ebene resultiert. 
Ein verlängerter AV-Kanal kann durch eine vermehrte Proliferation oder 
eine  vermehrte  Differenzierung  in  AV-Kanalzellen  hervorgerufen  werden. 
Zählexperimente  um 52  hpf deuten  daraufhin,  dass  sich  die Gesamtzahl  an 
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unterscheiden. Auch die Anzahl von Zellen im Atrium war nicht beeinflusst. Das 
lässt darauf schließen, dass in den Morphanten mehr ventrikuläre Zellen in AV-
Kanalzellen differenzieren. 
Der  AV-Kanal  ist  charakterisiert  durch  eine  lokale  Schwellung  der 
Herzgallerte. Während der zuvor beschriebenen Experimente fiel auf, dass in 
den Morphanten die Herzgallerte im AV-Kanal, aber auch im gesamten Herzen, 
stark  angeschwollen  ist.  Die  lokale  Schwellung  wird  durch  die  lokale 
Expression von bmp4, tbx2 und has2 kontrolliert. Interessanterweise war die 
Expression dieser Gene in den Morphanten stark expandiert, d.h. die Daten 
zeigen eine inverse Korrelation des BMP4-HAS2 Signaltransduktionsweges mit 
Nephronectin Expression. Um zu testen, ob Nephronectin tatsächlich diesen 
Signaltransduktionsweg  reguliert  und  dessen  Misregulation  die  Ursache  der 
beobachteten  Phänotypen  ist,  wurden  HAS2-  und  BMP4-
Inhibierungsexperimente  durchgeführt.  has2  Knockdown  in  den  Morphanten 
reduzierte  die  Anzahl  Alcam-positiver  endokardialer  AV-Kanalzellen  von  ≥  8 
Reihen  (183%  ±  32.2%  im  Vergleich  zur  Kontrolle)  zu  ≤  3  Reihen  (31%  ± 
11.9% im Vergleich zur Kontrolle) und einer Reduzierung der Expression des 
spezifischen endokardialen AV-Markers notch1b. Im Gegensatz dazu war die 
Expression der kardialen AV-Markergene bmp4 und cspg2 unverändert. Diese 
Daten  legen  nahe,  dass  Nephronectin  indirekt  die  Expression  von  HAS2 
steuert. Um herauszufinden, ob Npnt möglicherweise ein Regulator von BMP4 
ist, einem Regulator von HAS2, wurde dessen Rezeptor (Typ I BMP Rezeptor) 
pharmakologisch mit Dorsomorphin inhibiert. Die optimale Konzentration des 
Inhibitors  wurde  mittels  Western  Blot-Analyse  anhand  der  Phosphorylierung 
des  Mediators  Smad  bestimmt. Dorsomorphin  reduzierte  in  den  Morphanten 
die  Anzahl  Alcam-positiver  endokardialer  AV-Kanalzellen  von  ≥  8  Reihen 
(166% ± 32.7% im Vergleich zur Kontrolle) zu ≤ 6 Reihen (125.3% ± 10.7% im 
Vergleich zur Kontrolle) und verursachte eine Reduzierung der Expression des 
spezifischen  endokardialen  AV  Markers  notch1b,  aber  auch  von  has2  und 
cspg2. Diese  Daten deuten  daraufhin, dass Nephronectin ein Regulator des 
BMP4-HAS2 Signaltransduktionsweges ist. 
  Kürzlich  wurde  gezeigt,  dass  Nephronectin  als  Ligand  für  Integrin  α8 
fungiert.  Mittels  in  situ  Hybridisierungsexperimenten  konnte  allerdings  zu 
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werden,  obwohl  die  Expression  in  mehreren  anderen  Organen  beobachtet 
werden konnte.  
 
Diskussion 
Die Mechanismen, welche die Differenzierung des AV-Kanals kontrollieren sind 
kaum  verstanden  obwohl  einige  wichtige  Regulatoren  wie  Notch,  Tbx2  und 
BMP2  bekannt  sind.  Allerdings  sind  die  Gene,  die  diese  Regulatoren 
kontrollieren,  weitestgehend  unbekannt.  Die  während  dieser  Doktorarbeit 
erbrachten  Daten  identifizieren  Npnt  als  einen  neuen  Regulator  der  frühen 
Herzentwicklung  im  Zebrafisch.  Die  Daten  legen  nahe,  dass  Npnt  die 
Differenzierung des AV-Kanals über den BMP4-HAS2 Signaltransduktionsweg 
reguliert. 
Es wurde gezeigt, dass die Interaktion zwischen Endokard und Myokard 
eine entscheidende Rolle in der Induktion der Herzklappenentwicklung spielt 
(23,  123,  124).  Eine  Veränderung  der  EZM,  die  Endokard  und  Myokard 
trennen,  kann  anscheinend  diese  Interaktion  stören.  Knockdown  der  Gene 
cspg2  und  has2,  die  beide  für  die  Zusammensetzung  und  damit  die 
Eigenschaften der EZM wichtig sind, resultiert in einer reduzierten EZM und 
dem Ausbleiben der Herzklappenbildung (53, 60). Knockdown des Gens npnt 
resultiert überraschenderweise in einer vermehrten EZM-Produktion. Darüber 
hinaus resultiert der Npnt Knockdown in einem verlängerten AV-Kanal. Diese 
Daten deuten darauf hin, dass Npnt nicht nur als strukturelles Protein fungiert 
sondern als negativer Regulator der Differenzierung des AV-Kanals.  
Hurlstone und Mitarbeiter haben anhand ihrer Daten mit apc Mutanten 
vorgeschlagen,  dass  die  Differenzierung  des  Endokards  im  AV-Kanal  durch 
den  Wnt/β-catenin  Signaltransduktionsweg  vermittelt  wird  (49). 
Interessanterweise  sind  die  Phänotypen  der  npnt  Morphanten  und  der  apc 
Mutanten ähnlich. Die Herzen beider erscheinen normal um 36 hpf. Allerdings 
produzieren beide im Gegensatz zu Wildtyp Fischen eine erhöhte Menge an 
Herzgallerte. In apc Mutanten ist Wnt/β-catenin im gesamten Herzen aktiv und 
resultiert hier in has2 Expression um 72 hpf. Die Daten der vorliegenden Arbeit 
zeigen allerdings, dass der Wnt/β-catenin Signaltransduktionsweg um 52 hpf 
nicht aktiv ist und daher dessen Misregulation vermutlich nicht die Ursache für 
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Die  Daten  bzgl.  der  npnt  Morphanten  weisen  auf  die  Bedeutung  des 
BMP4-HAS2  Signaltransduktionsweges  hin.  Die  Bedeutung  von  BMP  wurde 
allerdings nur anhand von dem Inhibitor Dorsomorphin gezeigt. Es wird daher 
in  der  Zukunft  wichtig  sein,  diese  Ergebnisse  mit  einer  transgenen 
Zebrafishlinie  zu  verifizieren,  in  der  BMP  Rezeptoren  spezifisch  blockiert 
werden  können  (tg(hsp70:noggin3)).  Schließlich  erscheint  es  wichtig 
herauszufinden, wie Npnt den BMP Signaltransduktionsweg genau kontrolliert. 
Es ist möglich, dass das Myokard im Ventrikel und im Atrium einen Rezeptor 
exprimiert,  an  den  Npnt  bindet  und  die  Differenzierung  in  AV-Kanalzellen 
inhibiert. Ein möglicher Kandidat ist Integrin α8, das bisher als Npnt Rezeptor 
beschrieben  wurde  (85,  87).  Allerdings  konnte  in  dieser  Arbeit  keine 
Expression von Integrin α8 im Herzen nachgewiesen werden. Alternativ könnte 
Integrin αV als Rezeptor fungieren (130). Seine Expression wurde allerdings im 
Herzen bisher nicht genau charakterisiert. Aufgrund der Ca
2+-abhängigen EGF-
ähnichen  Domänen  könnte  Npnt  möglicherweise  auch 
Wachstumsfaktorrezeptoren aktivieren. So wurde z.B. gezeigt, dass Npnt über 
seine  Ca
2+-abhängigen  EGF-ähnichen  Domänen  die  Differenzierung  von 
Osteoblasten induziert (94). Ein ähnliches Phänomen wurde auch für das EZM-
Protein Versican beschrieben, dass mit seinen Ca
2+-abhängigen EGF-ähnichen 
Domänen Wachstumsfaktorrezeptoren binden kann (127, 128). Ein möglicher 
Rezeptor für Npnt sind die sogenannten ErbB Rezeptoren. ErbB Rezeptoren 
sind  wichtig  für  die  Herzklappenentwicklung  als  auch  für  die  Trabekulierung 
(28,  136).  Zudem  ist  bekannt,  dass  die  Ca
2+-abhängigen  EGF-ähnichen 
Domänen  mehrerer  Proteine  (z.B.  Versican,  EGF,  TGF-α,  Amphiregulin, 
Epiregulin,  Neuregulin)  an  die  extrazelluläre  Domäne  von  ErbB  Rezeptoren 
binden und diese aktivieren können (138). 
Anstatt als Ligand könnte Npnt allerdings auch die Verfügbarkeit bzw. 
die  Konzentration  von  BMP4  regulieren.  Npnt  könnte  nötig  sein,  um  die 
Eigenschaften  der  Herzgallerte  so  zu  regulieren,  dass  BMP4  nicht  von  der 
exprimierenden Zelle weg diffundieren und so seine Funktion nur lokal ausüben 
kann. Der Knockdown von Npnt würde folglich dazu führen, dass BMP4 aus 
dem  AV-Kanal  diffundiert  und  in  dem  Ventrikel  und  dem  Atrium,  die  BMP4 
Rezeptoren  exprimieren,  ektopisch  die  Differenzierung  des  AV-Kanals 
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Osteoblasten  beschrieben  (134).  Da  die  regulatorischen  Mechanismen  der 
Differenzierung  von  Osteoblasten und  der  Herzklappenentwicklung  sich  zum 
Teil  sehr  ähnlich  sind  (133),  sollte  dieser  Hypothese  in  der  Zukunft  nach 
gegangen werden. 
  Die Entdeckung, dass Nephronectin für die Herzentwicklung essentiell 
ist, ist aus mehreren Gründen von Bedeutung. Dies ist, meines Wissens nach, 
die erste Studie, die zeigt, dass Npnt transient im Herzen exprimiert ist. Diese 
Studie zeigt, dass Npnt für die Herzklappenentwicklung und die Trabekulierung 
des Herzens von Bedeutung ist. Die vorliegenden Daten etablieren Npnt als 
neuen  Regulator  für  den  BMP4-HAS2  Signaltransduktionsweg.  Die  Daten 
bestätigen  zudem  im  Zebrafisch,  dass  HAS2  eine  entscheiden  Rolle  für  die 
Differenzierung der Endothelzellen im AV-Kanal spielt. Schließlich könnte diese 
Studie  von  medizinischer  Relevanz  sein.  Defekte  in  der 
Herzklappenentwicklung  sind  für  20%  bis  30%  aller  angeborenen 
Herzerkrankungen  verantwortlich  (3).  Die  Ursache  für  die  meisten  dieser 
Erkrankungen ist jedoch unklar. 
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